

COL.LEGI OFICIAL DE QUÍMICS DE CATALUNYA
Secció Tècnica PATENTS

Ciclo de conferencias-coloquio:
"Las patentes en la actividad laboral del químico"

Cómo un químico puede formarse sobre patentes

Prof. Pascual Segura

Ldo. en química por la Univ. de Valencia y Dr. por la Univ. de Barcelona (UB)

Agente de la propiedad industrial de la UB y director de su Centro de Patentes

Elected member of the first Academic Advisory Board of the European Patent Academy, EPO

President de la Secció Tècnica PATENTS del Col.legi Oficial de Químics de Catalunya

Barcelona, 26 de mayo de 2010



Ciclo de conferencias-coloquios

LAS PATENTES EN LA ACTIVIDAD LABORAL DEL QUÍMICO

Organizado por la

Secció Tècnica Patents
del Col·legi de Químics de Catalunya

En colaboración con el

Centre de Patents
de la Universitat de Barcelona

Martes 16 de marzo de 2010

"Las patentes como salida profesional para los químicos: agencias, empresas y oficinas de patentes", por Bernabé Zea.

Jueves 15 de abril de 2010

"La importancia de las patentes para las empresas químicas y farmacéuticas, y la necesidad del conocimiento sobre patentes en el trabajo habitual del químico", por Bernabé Zea.

Martes 4 de mayo de 2010

"El químico como perito en conflictos de patentes", por Pascual Segura.

Miércoles 26 de mayo de 2010

"Cómo un químico puede formarse sobre patentes", por Pascual Segura.

COL.LEGI DE QUÍMICS DE CATALUNYA
Secció Tècnica PATENTS

Curs PATENTS QUÍMIQUES AL COL.LEGI

Sesión 6. Barcelona, 5 y 6 de marzo de 2008

***Qué se puede patentar en
biotecnología y biomedicina***

Lídia Casas

Bioquímica colegiada

Técnico de patentes y tutora del Centre de Patents de la Universitat de Barcelona

La documentación de todo el curso está disponible para descarga en www.quimics.cat (Seccions Tècniques / S.T. Patents)

Qué se puede patentar en química y farmacia

Montserrat Jané

Química colegiada

Técnico de patentes y tutora del Centre de Patents de la UB

Qualified European Patent Attorney

Socia de la agencia de patentes y marcas ZBM Patents



OEPM



Oficina Española
de Patentes y Marcas

www.oepm.es

Pag. Inicio

AVISOS Y NOTICIAS

La Directora General de la Oficina Española de Patentes y Marcas (OEPM) y el Rector de la Universidad de Barcelona han formalizado la voluntad de cooperación entre ambas entidades mediante la firma de un Convenio de Colaboración para la organización conjunta de actividades de información, divulgación y formación sobre propiedad industrial.

Abril 2006

Ps Castellana 75. Madrid



B.O.P.I.	Conócenos	Propiedad Industrial	Modalidades	Oficina Virtual
-----------------	------------------	-----------------------------	--------------------	------------------------

Oficina Virtual

individual o por lotes

- Solicitud-e de invenciones
- Solicitud de registro de Diseños Industriales
- Presentación de recursos



- Marcas**
- Nombres comerciales
- Patentes
- Modelo de utilidad
- Diseños industriales
- Topografías de productos semiconductores

Portales OEPM

- Información Tecnológica
- Calidad
- Piratería
- Archivo Histórico y Museo
- Acceso CCRR
- CEVI CEVIPYME

Agenda OEPM

Noticias

Premios al inventor europeo del año 2010

Marzo 2010 - Febrero 2011: "Curso práctico para preparar el European Qualifyin..."

Abril 2010: "Course on Japanese Patent System: Law, Case-law and Practice on J..."

Bases de datos

- Localizador de marcas
- Situación de expedientes
- Inventiones y Diseños en español: INVENES
- Inventiones en otros idiomas: esp@cenet
- Inventiones Latinoamericanas: Latipat
- Clasificación Internacional de Patentes
- Clasificación Internacional de Productos y Servicios (Marcas)

Formularios

- Tasas 2010**
- Otras Informaciones**
- Estadísticas
- Centros Regionales de Información en Propiedad Industrial
- Legislación
- Ayudas
- Empleo
- Perfil del Contratante

A continuación le presentamos las últimas noticias referentes a nuestra entidad. Si lo desea, puede buscar en el histórico de noticias que tiene habilitado en la parte inferior de ésta página.

Resultado de la búsqueda - Se mostrarán las 60 últimas noticias.

- ▶ 25-01-2010 / 22 de marzo 2010 - "Jornada de estudio y actualización en materia de patentes (Lunes de Patentes)"
- ▶ 25-01-2010 / Abril 2010: "Course on Japanese Patent System: Law, Case-law and Practice on JP Patents"
- ▶ 25-01-2010 / Marzo 2010 - Febrero 2011: "Curso práctico para preparar el European Qualifying Examination (EQE)"
- ▶ 12-01-2010 / Marzo y Junio 2010 (Barcelona), y Noviembre 2010 (Madrid): "Curso sobre patentes y modelos de utilidad: Fundamentos, Documentación, Transferencia y Redacción".
- ▶ 31-07-2008 / Septiembre 2008 - Junio 2010 - II Curso en Derecho Europeo de Patentes
- ▶ 26-04-2006 / Pago de tasas de solicitudes de Signos distintivos por internet.

UB

CEIPI

Módulo ampliado de Fundamentos

El sistema de patentes: políticas de protección, patentabilidad e infracción



Módulo de Documentación

Bases de datos y servicios de información tecnológica de la OEPM, la OEP y otras oficinas



Centre de Patents
de la Universitat de Barcelona



Módulo de Transferencia

Transferencia de patentes y de know-how:
redacción de contratos de cesión y de licencia

XXIII Edición, Barcelona, marzo y junio de 2010
XXIV Edición, Madrid, noviembre de 2010

Módulo ampliado de Redacción

La práctica de la redacción de memorias
y reivindicaciones

Curso sobre patentes y modelos de utilidad

Fundamentos
Documentación
Transferencia
Redacción

Módulo ampliado de Fundamentos

El sistema de patentes: políticas de protección, patentabilidad e infracción

Fechas

Barcelona: 1-4 de marzo o 28 de junio a 1 de julio

Madrid: 15-18 de noviembre

A quién va dirigido

A quien precise una introducción detallada a las patentes porque va a trabajar en el tema o prevea asistir a cualquiera de los otros módulos

Profesor

Bernabé Zea

Licenciado en química. Técnico en patentes y documentalista del Centro de Patentes de la UB. Agente de la Propiedad Industrial colegiado. Socio de ZBM Patents. Miembro de la Asociación Catalana de Peritos Judiciales.

Contenido

- **Introducción a la propiedad intelectual-industrial (PI).** Instituciones involucradas en la consecución y defensa de los derechos de PI. Objetivos del sistema de patentes: promoción de la innovación tecnológica. Modalidades de protección: derechos de autor, marcas, indicaciones geográficas, diseños y patentes. Competencia desleal. Secreto industrial. Para qué sirven las patentes y para qué no.
- **Principales conceptos relativos a las patentes.** Qué se puede patentar. Ejemplos sobre invenciones patentables y otro tipo de creaciones. Derechos conferidos por las patentes. El derecho negativo de impedir a los terceros la explotación de la invención patentada. Cómo las patentes por sí mismas no dan derecho a la explotación de las invenciones. Determinación de la titularidad y la inventoría: riesgos de su asignación incorrecta en una patente. Derechos del inventor y del titular.

Contenido (cont.)

- **Requisitos de patentabilidad.** Carácter técnico. Excepciones a la patentabilidad. Aplicabilidad industrial. Definición del estado de la técnica. Quién es el experto en la materia a efectos de patentabilidad. Novedad. Actividad inventiva. Determinación de la actividad inventiva mediante la aproximación problema-solución llevada a cabo por la EPO (*European Patent Office*). Indicios secundarios de actividad inventiva. Particularidades de los modelos de utilidad. Estado de la técnica aplicable a los modelos de utilidad. El concepto de novedad nacional de acuerdo con las decisiones del Tribunal Supremo.
- **Protección de las invenciones.** Política de empresa en relación con la propiedad industrial. Decisión de patentar frente al mantenimiento del secreto industrial. Aspectos básicos en la redacción de patentes. Identificación de las invenciones a partir de la información suministrada por el inventor. Cómo pasar de un producto a una invención. Tipos de reivindicaciones disponibles: entidad (producto) y actividad (usos, métodos y procedimientos) Qué, cómo, cuándo y dónde patentar.
- **Extensión de la protección a distintos países.** Derecho de prioridad como inicio de la protección. Familias de patentes: patentes equivalentes en diversos países. Procedimientos de tramitación de la protección en el extranjero: nacional en las diferentes oficinas, patente europea y solicitud internacional (PCT). Validación de patentes europeas: cambios debidos al Acuerdo de Londres. Costes asociados a la protección por patente: redacción de la patente, contestación a acciones oficiales, traducción, tasas de mantenimiento. Honorarios de trámite y tasas oficiales.
- **Política de protección.** Idioma de la solicitud prioritaria y oficina para la primera presentación. Aspectos sobre redacción: adaptación a las necesidades específicas de cada titular. Necesidad de primera solicitud en España. US *provisionals* como medio de conseguir una primera protección en Estados Unidos. Estrategia según la naturaleza del solicitante: universidades, centros públicos de investigación, pequeñas empresas dedicadas a investigación, grandes empresas con centros de investigación y empresas de genéricos. Preparación para superar una *IP due diligence* (auditoría que se llevará a cabo por terceros en el momento en que estén interesados en la compra o participación en los activos de propiedad industrial del titular).



Módulo ampliado de Fundamentos

El sistema de patentes: políticas de protección, patentabilidad e infracción

Contenido (cont.)

- **Interpretación de un documento de patente.** Identificación de las distintas partes del documento. Primera página como fuente de datos bibliográficos e interpretación de la situación registral del documento. Códigos INID asignados por todas las oficinas de patentes. Códigos de publicación. Duración de las patentes, incluyendo los cambios en España y Estados Unidos.
- **Infracción de patentes.** Derechos concedidos y actos prohibidos. Alcance de la protección de las reivindicaciones (independientes y dependientes). Regla de la simultaneidad de todos los elementos. Análisis elemento-por-elemento. Doctrina de los equivalentes. Infracción directa (literal o por equivalencia) e infracción indirecta (por contribución). Acciones judiciales. Inversión de la carga de la prueba. Diligencias de comprobación de hechos. Medidas cautelares. Consecuencias de la infracción.
- **Peculiaridades del sistema estadounidense.** El inventor como solicitante. *First to invent vs. first to file*. Procedimientos de interferencia para determinar la titularidad. Novedad mixta a diferencia de la novedad absoluta y mundial del sistema europeo. La existencia en la práctica de un "año de gracia". *Best mode*. Publicación de algunas solicitudes de patentes frente a la única publicación de la patente concedida. Cuadernos de laboratorio como prueba para determinación de la fecha de invención.

ÍNDICE del Módulo ampliado de Fundamentos

El sistema de patentes: políticas de protección, patentabilidad e infracción

Instituciones relacionadas con la PI	23
Bases y justificación del sistema de patentes	34
Distintas modalidades de protección y estadísticas	53
Derechos de autor (Copyright)	61
Marcas	80
Indicaciones geográficas	133
Competencia desleal	145
Diseño industrial	152
Introducción a la protección de la tecnología	173
El negocio de la investigación (Ejemplo sillas)	182
Caso práctico 1 – Estrategia de protección	190
Caso práctico 2 – ¿Invento patentable o no?	191
Caso práctico 3 – ¿Invento patentable o no?	192
Secreto industrial	193
Caso práctico 4 – Valor del secreto	204
El producto comercial (Viagra)	205
Caso Práctico 5 – Comprimidos de Viagra	218
Patentes e introducción requisitos de patentabilidad	220
Derechos de exclusiva que otorga una patente	223
Caso Práctico 6 – Pastilla jabón	22


Dependencia de patentes	230
Patente como título de propiedad	231
Derecho a la patente	233
Secreto y derecho de preuso	238
¿Qué se puede patentar?	243
Requisitos básicos de patentabilidad	256
Estado de la técnica	257
Novedad	261
Actividad inventiva	267
Ejemplo de patente (Toy ball)	284
Caso práctico 7 – Protección de invenciones “de selección”	297
Tipos de patentes	298
Modelos de utilidad	299
Motivos para patentar	307
Patentes en el sector de las TIC	310
Patentes en farmacia y química fina	313
Patentes en biotecnología	315
Política de patentes en la empresa	316
Redacción de patentes – Reivindicaciones	319
Caso práctico 8 - ¿Cuál es la invención?	331
Cuándo solicitar una patente	232
Dónde patentar – Elección de países	339

Estrategia de presentación de patentes – Vías de solicitud	342
Vía nacional	346
Vía PCT	349
Vía Europea	354
Acuerdo de Londres	363
Estadísticas relacionadas con la patente europea y EPAs	378
Función del Agente de Patentes	391
Caso práctico 9 – Estrategia de protección	394
Aspectos a decidir en una primera solicitud de patente	395
Opciones para presentar sol. prioritaria - Patentes secretas	396
Usuarios diferentes... Necesidades diferentes	408
Inventores particulares	409
Empresas dedicadas a la investigación	410
Universidades y centros públicos de investigación	412
Empresas innovadoras (multinacionales)	414
Empresas de genéricos (imitadoras)	417
Caso práctico 10 – Empresa de genéricos	427
Due Diligence	428
Solicitud vs. Concesión	434
Caso práctico 11 – Valor de una solicitud de patente	445
Caso práctico 12 - ¿Qué se puede patentar?	446
Familia de patentes	447

Derecho de prioridad	449
Caso práctico 13 – Familia de patentes	457
Interpretación de una patente	459
Caso práctico 14 - ¿Qué proteger?	482
Caso práctico 15 - ¿Qué proteger? – II	483
Infracción de patentes	484
Producto directamente obtenido	493
Doctrina de los equivalentes	494
Caso práctico 16 – Análisis de infracción	508
Caso práctico 17 – Patentabilidad	513
Caso práctico 18 – Aspirador revolucionario	514
Mantenimiento de una patente y tasas	515
Causas de nulidad	519
Derecho que confiere la patente - Agotamiento del derecho	525
Consecuencias de la infracción	527
Acciones frente a una posible infracción	529
Diligencias de comprobación de hechos	530
Medidas cautelares	531
Inversión de la carga de la prueba	533
Legislación española	535
Duración de las patentes	538
Patente en Estados Unidos	541

Aunque **un científico o ingeniero** no tenga nada que patentar, o no piense en el beneficio económico, en su vida profesional **no puede ignorar las patentes** porque:

- Son la mayor fuente de información técnica (más de un millón de solicitudes al año)
- En la mayoría de los casos **son la primera publicación** donde se publica esa información
- El **70-85%** de toda esta información técnica **no se publica por ningún otro medio.**



Módulo de Documentación

Bases de datos y servicios de información tecnológica de la OEPM, la OEP y otras oficinas

Fechas

Barcelona: 5 de marzo

Madrid: 19 de noviembre

A quién va dirigido

A cualquiera que tenga algún conocimiento sobre patentes, o que haya asistido al módulo de Fundamentos

Profesor

Carmen Toledo

Doctora en farmacia. Jefe del Área de Documentación y Búsquedas del Departamento de Patentes e Información Tecnológica, Oficina Española de Patentes y Marcas.

Contenido

- **Información en Internet.** Información administrativa: trámites ante la OEPM, solicitud electrónica, ayudas y subvenciones, publicaciones electrónicas (BOPI y Boletines de Vigilancia Tecnológica). Bases de datos oficiales de patentes, de ámbito internacional : *Esp@cenet*, *Epoline* (OEP) y *PatentScope* (OMPI). Bases de datos de patentes de oficinas nacionales: *INVENES* (oficina española), *PatFT* (oficina norteamericana), *PAJ* (oficina japonesa), *KIPRIS* (oficina coreana), bases de datos de las oficinas china, india, etc. Bases de datos no oficiales de patentes: *Google Patents*, *Boliven*, *Patent Lens*, *IP Newsflash*, *PatentMatic*, *FreePatentsOnline*, etc. Bases de datos de contenido jurídico.
- **Servicios de información tecnológica.** Informes tecnológicos de patentes, búsquedas retrospectivas e informes de vigilancia tecnológica a medida.

3.- Buscar los antecedentes

Aunque no esté en el mercado, habrá antecedentes, más o menos próximos. Hay que localizarlos (mediante búsqueda en bases de datos) para juzgar la novedad y actividad inventiva.



Lo primero que hay que hacer cuando se cree tener una invención patentable: buscar antecedentes en bases de datos de artículos (Medline, Excerpta Medica...) y de patentes (SciFinder...); evitar la divulgación prematura (congresos, artículos, tesis, tesinas...) que impida su patentabilidad; hablar con un experto.


ISI Web of Knowledge: <http://go5.isiknowledge.com/>

The screenshot shows the ISI Web of Knowledge homepage. At the top, there is a navigation bar with the logo and a dropdown menu for 'Products & Features'. Below the logo, a welcome message is displayed. A search bar is prominently featured with a 'SEARCH' button and a 'More information' link. The main content area is divided into 'Searchable Database Products' and 'Analytical Tools'. Under 'Searchable Database Products', several databases are listed, including 'Web of Science' (with 'Science Citation Index Expanded' highlighted in a red box), 'Current Contents Connect', 'ISI Proceedings', and 'Derwent Innovations Index' (also highlighted in a red box). Under 'Analytical Tools', 'Journal Citation Reports' and 'Essential Science Indicators' are listed. On the right side, there is a 'Sign In' section with input fields for 'E-mail Address' and 'Password', and a 'SIGN IN' button. Below that, there are sections for 'Citation Alerts' and 'My Journal List'. A red circle highlights the logos of the 'MINISTERIO DE EDUCACIÓN Y CIENCIA' and 'FECYT' in the top right corner. A yellow box with blue text points to these logos, stating 'Lo paga el MEC para organismos públicos'. Another yellow box with red text points to the 'Derwent Innovations Index' entry, stating '¡ El ISI no cubre patentes !'. A third yellow box with blue text points to the 'Derwent Innovations Index' entry, stating 'Derwent's World Patents Index (WPI) es la mejor base de datos comercial sobre patentes electromecánicas'.

Lo paga el MEC para organismos públicos

¡ El ISI no cubre patentes !


Derwent's World Patents Index (WPI) es la mejor base de datos comercial sobre patentes electromecánicas



La mayoría de universidades y muchas empresas son suscriptoras de SciFinder

SciFinder (en esta versión o en la versión web) de CAS cubre las patentes químico-farmacéuticas-biológicas de 50 oficinas/países (Medline, Excerpta Medica, Science Citation Index... no cubren patentes)

CAS resume e indiza los contenidos de muchas fuentes, produciendo bases de datos de gran calidad



*The CA Family is comprised of CA, CAPlus and CAOLD

SciFinder

- Es el sistema de información científico-técnica y de patentes, **integrado, exhaustivo y fácil de usar**, que CAS ofrece para su **uso directo** por el usuario final (no por el profesional, que sigue usando las bdd de STN Int.).
- Además de la **indización habitual** (*index terms, Registry Numbers, CAS roles...*), incorpora "**inteligencia de búsqueda**" adicional (detrás del telón) que **resuelve, de forma rápida y segura, la mayoría de necesidades** de información sin salir del sistema, facilitando el acceso al documento completo.
- **Integra** las bases de datos de CAS (CAplus, REGISTRY, CASREACT, CHEMCATS, CHEMLIST) y MEDLINE, con muchas posibilidades de **consultas cruzadas, incluidas subestructuras**.
- Más de 28M de refs. desde 1907 provenientes de más de 9.000 revistas y patentes de más de 50 oficinas. Más de 16M de refs. Medline desde 1950.
- Más de 33M de sustancias y unos 60M de biosecuencias (¡casi todas!)
- Más de 14M de reacciones. Más de 70M de fichas de 800 catálogos.



'ENVIAGRADOS Los efectos colaterales de la pastilla azul a los diez años de su nacimiento.

"VIAGRA ® nació para ayudar a los afectados de disfunción eréctil y se ha convertido en moda para muchos. A sus casi diez años de vida, los efectos colaterales de las pastillas sexuales son ya asunto social: uso abusivo, disgustos de pareja y malestar por hacer del acto competición y negocio." (EL PAÍS SEMANAL 14.10.2007)

Otro "efecto colateral" de sus diez años en el mercado será la **aparición de genéricos de sildenafilo en España en 2008, si las patentes no lo pueden retrasar** (al menos hasta 2013, como donde hay reivindicación de producto sobre el principio activo).



VIZARSIN de KERN PHARMA

Primer sildenafilo distinto de Viagra® lanzado en España

A Viagra le sale el primer «clon»

6 Diciembre 09 - Sergio Alonso

Compártelo:

«Corregir la disfunción eréctil está, por fin, más al alcance de todos» es el lema con el que se anunciará el fármaco.

MADRID- Viagra, el mítico producto contra la disfunción eréctil que revolucionó las terapias sexuales y que inauguró en todo el mundo la era de los medicamentos «galácticos», va a tener pronto un clon. No se trata de ninguno de los otros dos fármacos innovadores destinados a combatir la impotencia que existen ya en el mercado, y que presentan un diferente mecanismo de acción para lograr la misma meta: Cialis y Levitra. Se trata del primer medicamento genérico del producto y, según ha podido saber LA RAZÓN, va a comercializarse de manera inminente, en cuestión de días, en las oficinas de farmacia españolas.

Además, su precio será mucho más bajo que el fármaco original, al expirar en nuestro país los derechos de patente del mismo. Este genérico del principio activo que compone Viagra, el sildenafilo, se denominará Vizarsin, y ha comenzado ya a anunciarse con el lema de «corregir la disfunción eréctil está, por fin, más al alcance de todos». El fármaco, de ingestión oral, se comercializará por parte del laboratorio Kern Pharma en un total de



1. NOMBRE DEL MEDICAMENTO

Vizarsin 25 mg comprimidos recubiertos con película
Vizarsin 50 mg comprimidos recubiertos con película
Vizarsin 100 mg comprimidos recubiertos con película

2. COMPOSICIÓN CUALITATIVA Y CUANTI

El principio activo es sildenafilo.

Todo es intuitivo:
sólo hay que clicar.
Se usa una vez... y ya
nunca se olvida

SciFinder Scholar

File Edit View Task Tools Help

NewTask Back Forward Print Save As FullText Prefs Database History Internet Help Exit

New Task

Select One:

- Explore
Search for scientific information.
- Locate
Find a specific reference or substance.
- Browse
Scan tables of contents of my favorite journals.

Explore

Select One:

- Explore Literature**
 - Research Topic
 - Author Name
 - Company Name / Organization
- Explore Substances**
 - Chemical Structure
 - Molecular Formula
- Explore Reactions**
 - Reaction Structure

Locate

Select One:

- Locate Literature**
 - Bibliographic Information
Examples: journal name, title
 - Document Identifier
Examples: patent number, CA abstract number
- Locate Substances**
 - Substance Identifier
Examples: chemical name, CAS Registry Number


Browse Journal Table of Contents

File Edit Tools Help

- Accounts of Chemical Research
- ACH - Models in Chemistry
- ACS Chemical Biology
- ACS Symposium Series

Accounts of Chemical Research
Volume: 39 Issue: 10 2006

Cooperative Binding and Multiple Recognition by Bridged Bis(β -cyclodextrin)s with Functional Linkers Liu, Yu; Chen, Yong. Journal; General Review CAPLUS



139755-83-2

catálogos comerciales

~1022 References
REGISTRY sildenafilo

Refinar por tipo de documento (patente)

Refine by Document Type

Select the Document Type(s) of interest:

Biography Dissertation Patent

Book Editorial Preprint

Bibliographic Information

Preparation of pyrazolo[4,3-d]pyrimidin-7-ones as cardiovascular agents. Bell, Andrew Simon; Brown, David; Terrett, Nicholas Kenneth. (Pfizer Ltd., UK; Pfizer Inc.). Eur. Pat. Appl. (1992), 26 pp. CODEN: EPXXDW EP 463756 A1 19920102 Designated States R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. Patent written in English. Application: EP 91-305137 CAN 116:255626 AN 1992

Patent Family Information

Patent No.	Kind	Date	
Application No.		Date	
EP 463756	A1	19920102	EP
1991-305137	19910607		
EP 463756	B1	19950419	

Ref. CA de la 1ª familia de patentes

European Patent Office

English Deutsch Français

In my patents list | Print

Pyrazolopyrimidinone antianginal agents.

Bibliographic data Description Claims Mosaics

Publication number: EP0463756
Publication date: 1992-01-02

acceso al documento completo

ARTÍCULO CIENTÍFICO

- **TÍTULO** largo y muy descriptivo
- **AUTORES** (muchos; a veces alguno "ficticio")
- **INTRODUCCIÓN** con muchas citas a artículos (revisión bibliográfica)
- **RESULTADOS Y DISCUSIÓN**: justificación teórica (los porqués); distinción entre lo real (**en presente**) y lo posible (**en condicional**); trascendencia en relación con otros estudios; perspectivas (**en futuro**).
- **EXPERIMENTAL** (Materiales y Métodos; Ejemplos): Lo realmente realizado (**en pasado**), detallado para que sea reproducible.

PATENTE

- **TÍTULO** críptico y poco descriptivo
- **INVENTORES** (pocos y "reales") y **PROPIETARIOS** (registrados)
- **ESTADO DE LA TÉCNICA** con pocas citas a patentes; **problema técnico** planteado.
- **EXPLICACIÓN GENERAL**: soporte de las reivindicaciones, que muchas son extrapolaciones (**en presente**); **solución al problema**; uso industrial y ventajas.
- **EXPLICACIÓN DETALLADA**: lo realmente realizado (**en pasado**) y/o *paper examples* (**en presente**). **Dibujos y biosecuencias** al final.
- **REIVINDICACIONES**: definiciones de entidades/actividades protegidas

espacenet — Number Search - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://ep.espacenet.com/numberSearch?locale=en_EP

espacenet — Number Se...

European Patent Office

Home | Contact English Deutsch Français Help index ? Learn more about searching Get **assistance**

Number Search

1. Database

Select patent database:

Worldwide - full collection of published patent applications from 80+ countries

2. Enter Number

Enter either application, publication or priority number with or without country code prefix, or NPL reference number

Number: WO2008014520

EP0463756

SEARCH ← AR



Quick Search

Advanced Search

Number Search

Last result list

My patents list

0

Classification Search

Get assistance

Quick Help

- » Why are some tabs deactivated for certain documents?
- » Why does a list of documents with the heading "Also published as" sometimes appear, and what are these documents?
- » What does A1, A2, A3 and B stand for after an EP publication number in the "Also published as" list?
- » What is a cited document?
- » What are citing documents?

In my patents list | Print

[Return to result list](#)

Pyrazolopyrimidinone antianginal agents.

Bibliographic data

Description

Claims

Mosaics

Original document

INPADOC legal status

Publication number: EP0463756 (A1)

Publication date: 1992-01-02

Inventor(s): BELL ANDREW SIMON [GB]; BROWN DAVID [GB]; TERRETT NICHOLAS KENNETH [GB] +

Applicant(s): PFIZER LTD [GB]; PFIZER [US] +

Classification:

- international: A61K31/505; A61K31/519; A61P9/00; A61P9/08; A61P9/10; A61P9/12; C07D231/00; C07D231/02; C07D239/00; C07D239/08; C07D487/04; A61K31/505; A61K31/519; A61P9/00; C07D231/00; C07D239/00; C07D487/00; (IPC1-7): A61K31/505; A61K31/635; C07D487/04

- European: C07D487/04

Application number: EP19910305137 19910607

Priority number(s): GB19900013750 19900620

[View INPADOC patent family](#)

[View list of citing documents](#)

[View document in the European Register](#)

Also published as:

- EP0463756 (B1)
- ZA9104707 (A)
- RU2114114 (C1)
- RU2047617 (C1)
- PT98011 (A)
- PT98011 (B)
- PL166490 (B1)
- NZ238586 (A)
- NO912366 (A)
- NL990005 (I1)
- LU90360 (A9)
- KR940006628 (B1)
- JP6041133 (A)
- IL98482 (A)
- IE912094 (A1)
- IE66040 (B1)
- HU218945 (B)
- HK219496 (A)
- FI913017 (A)
- FI95132 (B)
- FI95132 (C)
- ES2071919 (T3)
- EG19651 (A)



19



Europäisches Patentamt
European Patent Office
Office européen des brevets



11 Publication number:

0 463 756 B1

12

EUROPEAN PATENT SPECIFICATION

45 Date of publication of patent specification: **19.04.95** 51 Int. Cl.⁶: **C07D 487/04**, A61K 31/505,
A61K 31/635

21 Application number: **91305137.1**

22 Date of filing: **07.06.91**

The file contains technical information submitted after the application was filed and not included in this specification

EP 463.756 B1 (1/4): de la primera familia de patentes de Pfizer sobre sildenafil

54 **Pyrazolopyrimidinone antianginal agents.**

30 Priority: **20.06.90 GB 9013750**

43 Date of publication of application:
02.01.92 Bulletin 92/01

235 East 42nd Street
New York, N.Y. 10017 (US)

84 Designated Contracting States:
BE CH DE DK ES FR GR IT LI LU NL SE AT

54 **Pyrazolopyrimidinone antianginal agents.**

30 Priority: **20.06.90 GB 9013750**

43 Date of publication of application:
02.01.92 Bulletin 92/01

45 Publication of the grant of the patent:
19.04.95 Bulletin 95/16

84 Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

56 References cited:
EP-A- 0 201 188

PATENT ABSTRACTS OF JAPAN unexamined applications, C field, vol. 13, no. 56, February 8, 1989 THE PATENT OFFICE JAPANESE GOVERNMENT page 10 C 566

73 Proprietor: **Pfizer Limited**
Ramsgate Road
Sandwich
Kent CT13 9NJ (GB)

84 Designated Contracting States:
GB

73 Proprietor: **PFIZER INC.**

235 East 42nd Street
New York, N.Y. 10017 (US)

84 Designated Contracting States:
BE CH DE DK ES FR GR IT LI LU NL SE AT

72 Inventor: **Bell, Andrew Simon**
Pfizer Central Research
Sandwich,
Kent CT13 9NJ (GB)

Inventor: **Brown, David, Dr.**
Pfizer Central Research
Sandwich,
Kent CT13 9NJ (GB)

Inventor: **Terrett, Nicholas Kenneth, Dr.**
Pfizer Central Research
Sandwich,
Kent CT13 9NJ (GB)

74 Representative: **Moore, James William, Dr.**
Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ (GB)

3 756 B1


Description

This invention relates to a series of pyrazolo[4,3-d]pyrimidin-7-ones, which are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE), having utility in a variety of therapeutic areas including the treatment of various cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

The compounds of the invention exhibit selectivity for inhibition of cGMP PDEs rather than cyclic adenosine 3',5'-monophosphate phosphodiesterases (cAMP PDEs) and, as a consequence of this selective PDE inhibition, cGMP levels are elevated, which in turn can give rise to beneficial platelet anti-aggregatory, anti-vasospastic and vasodilatory activity, as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF) and nitrovasodilators. Thus the compounds have utility in the treatment of a number of disorders, including stable, unstable and variant (Prinzmetal) angina, hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency e.g. post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).

European patent application EP-A-0201188 discloses certain pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists and PDE inhibitors, useful in the treatment of cardiovascular disorders such as heart failure or cardiac insufficiency. However these compounds are neither particularly potent PDE inhibitors, nor are they claimed to be selective inhibitors of cGMP PDE.

The compounds of the present invention are of the formula (I):



A particularly preferred group of compounds of the formula (I) is that wherein R¹ is methyl; R² is n-propyl; R³ is ethyl, n-propyl or allyl; R⁴ taken together with the nitrogen atom to which it is attached completes a 4-N-(R⁶) piperazinyl group; R⁵ is H; and R⁶ is H, C₁-C₃ alkyl or 2-hydroxyethyl.

Especially preferred individual compounds of the invention include:

20 5-[2-allyloxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-[2-ethoxy-5-(piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

25 5-[2-ethoxy-5-(4-methylpiperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;


5-{2-ethoxy-5-[4-(2-propyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;


5-{2-ethoxy-5-[4-(2-hydroxyethyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

30 1-methyl-5-[5-(piperazinylsulphonyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

and 5-[5-[4-(2-hydroxyethyl)piperazinylsulphonyl]-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

35 The compounds of the general formula (I) may be prepared by the reaction of a compound of the general formula (II):






(III)

wherein R⁴ and R⁵ are as previously defined.

The reaction is generally carried out at room temperature, preferably in the presence of a solvent, for example an alkanol containing one to three carbon atoms, using an excess of (III) to scavenge the acid by-product (HY).

Compounds of the general formula (II) may be prepared from compounds of the general formula (IV):





(IV)

(wherein R¹, R² and R³ are as previously defined) by the application of known methods for the introduction of a SO₂Y group (wherein Y is as previously defined) into an aromatic ring, for example, when Y represents a chlorine atom, by the action of chlorosulphonic acid at or near 0° C.

When R³ is a group susceptible to removal under the chlorosulphonylation conditions, e.g. allyl, said group can be introduced in the final stage of the synthesis. Thus the phenol of the general formula (IV), wherein R³ is H, and R¹ and R² are as previously defined, which is obtainable by Pd⁰-mediated deprotection of the O-allyl analogue as illustrated by Example 25, is chlorosulphonylated to provide a compound of the general formula (II), wherein Y is Cl, R³ is H, and R¹ and R² are as previously defined. The

Compounds of the general formula (IV) may be prepared from compounds of the general formula (V):




15


In an alternative cyclisation procedure, compounds of the general formula (IV) may be obtained by treatment of (V) with polyphosphoric acid at or near 140 °C for 6-18 hours.

Compounds of the general formulae (V) and (VI) may be prepared from compounds of the general formulae (VII) and (VIII) respectively:

30



35



40

Phosphodiesterase activity

20 Compound affinities for cGMP and cAMP PDEs are assessed by determination of their IC₅₀ values (the concentration of inhibitor required for 50% inhibition of enzyme activity). The PDE enzymes are isolated from rabbit platelets and rat kidney, essentially by the method of W.J. Thompson et al. (Biochem., 1971 10, 311). The calcium/calmodulin (Ca/CAM)-independent cGMP PDE and the cGMP-inhibited cAMP PDE enzymes are obtained from rabbit platelets whilst, of the four major PDE enzymes of the rat kidney, the
25 Ca/CAM-dependent cGMP PDE (fraction I) is isolated. Assays are performed using a modification of the "batch" method of W.J. Thompson and M.M. Appleman (Biochem., 1979, 18, 5228). Results from these tests show that the compounds of the present invention are potent and selective inhibitors of both cGMP PDEs.

30 Platelet anti-aggregatory activity

This is assessed by the determination of a compound's ability to inhibit platelet aggregation in vitro induced by platelet activating factor (PAF), and to potentiate the platelet antiaggregatory action in vitro of activators of guanylate cyclase such as nitroprusside and EDRF. Washed platelets are prepared essentially
35 by the method of J.F. Mustard et al. (Methods in Enzymol., 1989, 169, 3) and aggregation is determined using standard turbidimetric techniques as described by G.V.R. Born, J. Physiol. (Lond), 1962, 162, 67P.

Antihypertensive activity

40 This is assessed following intravenous or oral administration of a compound to spontaneously hypertensive rats. Blood pressure is recorded via a cannula implanted in the carotid artery of either conscious or anaesthetised animals.

Thus the invention provides a pharmaceutical composition comprising a compound of the formula (I), or
5 a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in medicine, particularly for the treatment of angina, hypertension, heart failure or atherosclerosis.

The invention further provides the use of a compound of the formula (I), or a pharmaceutically
10 acceptable salt thereof, for the manufacture of a medicament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency e.g. post-PTCA, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma, or diseases characterised by disorders of gut motility, e.g. IBS.

The invention also includes any novel intermediates disclosed herein such as those of formulae (II) and
15 (IV).

The preparation of the compounds of the invention will now be more particularly illustrated by reference to the following experimental Examples. The purity of the compounds was routinely monitored by thin layer chromatography (TLC) using Merck Kieselgel 60 F₂₅₄ plates. ¹H-Nuclear magnetic resonance spectra were recorded using a Nicolet QE-300 spectrometer and were in all cases consistent with the proposed structures.

20

EXAMPLE 1

1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester

25 A mixture of 3-n-propylpyrazole-5-carboxylic acid ethyl ester (24.1 g, 0.132 mol) (prepared by the method of Chem. Pharm. Bull., 1984, 32, 1568) and dimethyl sulphate (16.8 g, 0.133 mol) were heated to 90 °C for 2.5 hours. The mixture was dissolved in dichloromethane and the solution washed with sodium carbonate solution. The organic phase was separated, dried (MgSO₄) and evaporated under vacuum to give a solid. Chromatography on silica gel (300 g), eluting with dichloromethane gave the product as a colourless
30 oil (20.4 g, 79%). R_f 0.8 (silica; dichloromethane, methanol, acetic acid; 80:20:1).

36

5



10

15

20

25


30

Example		% yield	m.p. (°C)	Analysis % (Theoretical in brackets)		
				C	H	N
10		51	161-162	54.82 (54.77)	6.13 (6.13)	17.95 (18.25)
11		79	194-196	54.63 (54.75)	6.47 (6.39)	16.50 (16.65)
12		88	187-189	55.61 (55.68)	6.23 (6.37)	17.74 (17.71)

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. A compound of the formula:



and pharmaceutically acceptable salts thereof.

EP 463.756 B1 (2/4): de la primera familia de patentes de Pfizer sobre sildenafil

4. A compound as claimed in Claim 3 wherein said compound is selected from:
5-{2-ethoxy-5-[4-(2-propyl)piperazinylsulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; **sildenafil**

6. A compound of the formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 4, for use in medicine, particularly for the treatment of angina, hypertension, heart failure or atherosclerosis.


reivindicación al estilo primer uso terapéutico

7. The use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 4, for the manufacture of a medicament, particularly for the treatment of angina, hypertension, heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

8. A compound of the formula:

reivindicación de segundo uso terapéutico a la suiza

producto químico intermedio
(no farmacéutico)




EP 463.756 B1 (3/4): de la primera familia de patentes de Pfizer sobre sildenafil

Estos tipos de reivindicaciones no eran patentables en España hasta el 7.10.1992. Pero está sub-judice una interpretación contraria, basada en el ADPIC


Claims for the following Contracting State : **ES**

1. A process for preparing a compound of the formula:


¡Hasta el 7.10.1992
ESPAÑA Y GRECIA
FUERON DIFERENTES!



and pharmaceutically acceptable salts thereof, which comprises reacting a compound of the formula:




wherein R¹, R² and R³ are as previously defined and Y is chloro, bromo or fluoro, with a compound of the formula:




Claims for the following Contracting State : **GR**

1. A process for preparing a compound of the formula:



7. A compound of the formula:

producto químico
intermedio
(no farmacéutico)



**EP 463.756 B1 (4/4): de la
primera familia de patentes de
Pfizer sobre sildenafil**

①9



OFICINA ESPAÑOLA DE
PATENTES Y MARCAS

ESPAÑA

①1 N.º de publicación: **ES 2 071 919**

⑤1 Int. Cl.⁶: C07D 487/04

A61K 31/505

A61K 31/635

**Validación en España de la EP
463.756 B1: primera familia de
patentes de Pfizer sobre sildenafil**

①2

TRADUCCION DE PATENTE EUROPEA

T3

⑧6 Número de solicitud europea: **91305137.1**

⑧6 Fecha de presentación : **07.06.91**

⑧7 Número de publicación de la solicitud: **0 463 756**

⑧7 Fecha de publicación de la solicitud: **02.01.92**

⑤4 Título: **Agentes antianginosos de pirazolopirimidina.**

③0 Prioridad: **20.06.90 GB 9013750**

⑦3 Titular/es: **Pfizer Inc.**
235 East 42nd Street
New York, N.Y. 10017, US

REIVINDICACIONES


1. Un procedimiento para la preparación de un compuesto de fórmula

5

10

15

20



en la que



15 2. Un procedimiento de acuerdo con la Reivindicación 1 en el que R^1 , R^2 , R^4 y R^5 son de acuerdo con la Reivindicación 1, y R^3 es H, seguido de O-alkilación del fenol y conversión opcional del producto requerido en una sal farmacéuticamente aceptable.

20 3. Un procedimiento de acuerdo con la Reivindicación 1 o Reivindicación 2 en el que R^1 , R^4 y R^5 son de acuerdo con la Reivindicación 1, y R^3 es de acuerdo con la Reivindicación 1 o Reivindicación 2, en el que R^2 contiene un sustituyente hidroxilo protegido por acetilo o benzosilo, siendo separado dicho grupo protector posteriormente por hidrólisis con bases antes de la conversión opcional del producto requerido en una sal farmacéuticamente aceptable.



Texto a buscar

B.O.P.I.	Conócenos	Propiedad Industrial	Modalidades	Oficina Virtual
-----------------	------------------	-----------------------------	--------------------	------------------------

Oficina Virtual

individual o por lotes

- Solicitud-e de invenciones
- Solicitud de registro de Diseños Industriales
- Presentación de recursos



- Marcas**
- Nombres comerciales
- Patentes
- Modelo de utilidad
- Diseños industriales
- Topografías de productos semiconductores

- Portales OEPM**
- Información Tecnológica
 - Calidad
 - Piratería
 - Archivo Histórico y Museo
 - Acceso CCRR
 - CEVI CEVIPYME

Noticias

Premios al inventor europeo del año 2010

Marzo 2010 - Febrero 2011: "Curso práctico para preparar el European Qualifyin..."

Abril 2010: "Course on Japanese Patent System: Law, Case-law and Practice on J..."

- Bases de datos**
- Localizador de marcas
 - Situación de expedientes
 - Inventiones y Diseños en español: INVENES
 - Inventiones en otros idiomas: esp@cenet
 - Inventiones Latinoamericanas: Latipat
 - Clasificación Internacional de Patentes
 - Clasificación Internacional de Productos y Servicios (Marcas)

- Formularios**
- Tasas 2010**
- Otras Informaciones**
- Estadísticas
 - Centros Regionales de Información en Propiedad Industrial
 - Legislación
 - Ayudas
 - Empleo
 - Perfil del Contratante

Agenda OEPM

21 C 9900010 (5)

22 12-03-1999

Fecha de concesión: 12-02-2002

73 US Pfizer Inc
235 East 42ND Street
New York, New York 10017 U

68 2071919

54 **Agentes antianginosos de pirazolopirimidinona.**

92 EU/1/98/077/001-012 del 14-09-1998

93 UE EU/1/98/077/001-012 del 14-09-1998

94 14-09-2013

95 Sildenafil (viagra).

**Certificado
Complementario de
Protección (CCP) de
sildenafil en España,**
que extiende la protección
relativa al mismo de la
patente ES 2.071.919
(validación en España de
EP 463.756 B1) hasta el
14.09.2013

(BOPI 1.03.2002)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 702 555 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
11.03.1998 Bulletin 1998/11

(21) Application number: **94916236.6**

(22) Date of filing: **13.05.1994**

(51) Int. Cl.⁶: **A61K 31/505**

**EP 702.555 B1 (1/2): de la
segunda familia de patentes de
Pfizer sobre sildenafilo**

(54) **PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE**

PYRAZOLPYRIMIDINONE FÜR DIE BEHANDLUNG VON IMPOTENZ

PYRAZOLOPYRIMIDINONES UTILISEES POUR TRAITER L'IMPUISSANCE

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE**

(30) Priority: **09.06.1993 GB 9311920**

(43) Date of publication of application:
27.03.1996 Bulletin 1996/13

(73) Proprietors:
• **Pfizer Limited**

• **TERRETT, Nicholas Kenneth**
Sandwich Kent CT13 9NJ (GB)


(74) Representative:
Moore, James William, Dr. et al
Pfizer Limited
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)

(56) References cited:
EP-A- 0 463 756

EP-A- 0 526 004

Claims

1. The use of a compound of formula (I):



EP 702.555 B1: de la segunda familia de patentes de Pfizer sobre sildenafil

or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man.

6. The use according to claim 5 wherein the compound of formula (I) is 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.
8. The use of a compound of formula (I) as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of female sexual dysfunction. profético (sin pruebas)
9. The use according to any one of claims 1 to 8 wherein the medicament is adapted for oral treatment.
10. The use of a cGMP PDE inhibitor, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic oral treatment of erectile dysfunction in man. ¡intolerable! (equivale a proteger el mecanismo de acción)
11. The use according to claim 10 wherein the inhibitor is a cGMP PDE_V inhibitor.

espacenet — Bibliographic data - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&at=3

espacenet — Bibliograph... European Patent Office

Home | Contact English Deutsch Français Help index ?

In my patents list | Print [Return to result list](#)

PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE

Bibliographic data Description Claims Mosaics Original document INPADOC legal status

Publication number: EP0702555 (A1)
Publication date: 1996-03-27
Inventor(s): ELLIS PETER [GB]; TERRETT NICHOLAS KENNETH [GB] +
Applicant(s): PFIZER LTD [GB]; PFIZER RES & DEV [IE] +
Classification:
 - international: **A61K31/00; A61K31/505; A61K31/519; A61K31/522; A61K31/529; A61K31/535; A61K45/00; A61P13/02; A61P15/00; A61P15/10; C07D487/04; A61K; A61K31/00; A61K31/505; A61K31/519; A61K31/529; A61K31/535; A61K45/00; A61P13/00; A61P15/00; C07D487/00; (IPC1-7): A61K31/505**
 - European: **A61K31/505; A61K31/535**
Application number: EP19940916236 19940513
Priority number(s): WO1994EP01580 19940513; GB19930011920 19930609

[View INPADOC patent family](#)
[View list of citing documents](#)
[View document in the European Register](#)

Also published as:

- EP0702555 (B1)
- WO9428902 (A1)
- ZA9404018 (A)
- US6469012 (B1)
- RU2130776 (C1)
- PL311948 (A1)
- NZ314110 (A)
- NZ266463 (A)
- NO321622 (B1)
- NO325558 (B1)
- NO954757 (A)
- LV12269 (B)
- KR100262926 (B1)
- JP2005097304 (A)
- JP9503996 (T)
- JP11263728 (A)
- JP11286444 (A)
- IL121836 (A)
- IL109873 (A)
- GR3026520 (T3)
- FI955911 (A)
- ES2113656 (T3)
- ECSP941102 (A)
- DK0702555 (T3)

Quick Help

- » Why are some tabs deactivated for certain documents?
- » Why does a list of documents with the heading "Also published as" sometimes appear, and what are these documents?
- » What does A1, A2, A3 and B stand for after an EP publication number in the "Also published as" list?
- » What is a cited document?
- » What are citing documents?
- » What information will I find

Register Plus - EP94916236 - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

epoline.org https://register.epoline.org/espacenet/application;jsessionid=... Google

espacenet — Bibliographic... Register Plus - EP949...

European Patent Office

Home Contact Deutsch English Français Legal Notices

Advanced Search SmartSearch Search Results Download XML Data Print Open in esp@cenet@ Help

Search Publication No. EP0702555 Search

SmartSearch: publication = EP0702555

Open recent Open

EP0702555 - PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE Show history

[Right-click to bookmark this link]

Status	Patent revoked <i>Database last updated on 24.05.2010</i>		
Most recent event	28.11.2008	Lapse of the patent in a contracting state	published on 31.12.2008 [2009/01]
Applicant(s)	For: GB Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ / GB		
	For: AT BE CH DE DK ES FR GR IE IT LI LU NL PT SE		

About this file

- Legal status
- Event history
- Citations
- Patent family
- All documents

Quick Help

- » What kind of information can be found in "Show history"?
- » What kind of information can be found under "Status"?
- » What do the dates in square brackets refer to?
- » What does N/P stand for?
- » Why has the link to the decision not been activated yet?
- » What does the letter in

Register Plus - EP94916236 - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

epoline.org https://register.epoline.org/espacenet/application;jsessionid=... Google

espacenet — Bibliographic... Register Plus - EP949...

	16.07.2001	Date of oral proceedings
	11.10.2001	Despatch of communication that the patent will be revoked
	11.10.2001	Despatch of minutes of oral proceedings
	01.02.2005	Legal effect of revocation of patent [2005/47]
Appeal following opposition	12.11.2001	Appeal received No. T1212/01 
	17.01.2002	Statement of grounds filed
	03.02.2005	Result of appeal procedure: appeal of the proprietor was rejected
	01.02.2005	Date of oral proceedings
	04.02.2005	Minutes of the oral proceedings despatched
Fees paid	Renewal fee	
	27.03.1996	Renewal fee patent year 03
	10.04.1997	Renewal fee patent year 04
Lapse	GB	13.05.2003
		[2009/01]
Cited in	International search	[XD] EP0463756 ↻
		[XD] EP0526004 ↻
		[X] BR. J. PHARMAC. vol. 81, no. 4 , 1984 pages 665 - 674 A. BOWMANN ET AL. 'Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle'
		[X] AM. J. PHYSIOL. vol. 264 , February 1993 pages H419 - H422 F. TRIGO-ROCHA ET AL. 'Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs'

DG3: DBA case T 1212/01 - 3.3.2 - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

  <http://legal.european-patent-office.org/dg3/biblio/t011212eu1.htm>

 espacenet — Bibliographic...  Register Plus - EP94916236  DG3: DBA case T 1212... 



EPO boards of appeal decisions

[homepage](#) => [search & index](#) => [boards of appeal decisions](#)

Search mask		List of updates	
Date of decision	03 February 2005	Case number	T 1212/01 - 3.3.2
Application number	94916236.6		
IPC	A61K31/505	Proceedings Language	EN
Title of the application	Pyrazolopyrimidinones for the treatment of impotence		
Applicant name	Pfizer Limited, et al	Opponent name	VIVUS INC. ICOS Corp. SCHERING-PLOUGH

- View the [full document](#) as PDF file 
- [Voll-Dokument](#) als PDF Dokument betrachten
- Visualiser le [document complet](#) au format PDF



3EB7CBDBd01 - Adobe Reader

Archivo Edición Ver Documento Herramientas Ventana Ayuda

1 / 58 104%

Buscar

BESCHWERDEKAMMERN BOARDS OF APPEAL OF CHAMBRES DE RECOURS
DES EUROPÄISCHEN THE EUROPEAN PATENT DE L'OFFICE EUROPEEN
PATENTAMTS OFFICE DES BREVETS

Internal distribution code:
(A) [] Publication in OJ
(B) [] To Chairmen and Members
(C) [X] To Chairmen
(D) [] No distribution

D E C I S I O N
of 3 February 2005

Case Number: T 1212/01 - 3.3.2
Application Number: 94916236.6
Publication Number: 0702555
IPC: A61K 31/505
Language of the proceedings: EN
Title of invention:

Headword:

Pyrazolopyrimidinones for the treatment of impotence/PFIZER
LIMITED ET AL

Relevant legal provisions:

EPC Art. 123(2), 56

EPA Form 3030 06.03

- 2 -

Keyword:

"Main and auxiliary requests 1 and 2 - added matter - yes"

"Auxiliary requests 3 to 5 - inventive step - no"

"Neither technical prejudice nor commercial success
establishes inventive step"

Decisions cited:

T 0019/81, T 0060/82, T 0119/82, T 0104/83, T 0048/86,

"Viagra use patent invalid, court rules"

Pfizer's patent on the use of phosphodiesterase-5 (PDE(V)) inhibitors for treatment of male erectile dysfunction (MED) is invalid, the UK Court of Appeal ruled at the end of January. The Court was considering an appeal by Pfizer against a High Court judgement in November 2000 that the patent was **invalid on the grounds of obviousness**.

Pfizer originally sought patent protection for a number of PDE(V) inhibitors, including sildenafil citrate (Viagra), in 1991, but its patent application referred only to their potential in the treatment of cardiovascular disorders, and made no mention of erectile dysfunction. The patent relating to the use of PDE(V) inhibitors in the treatment of MED was not filed until June 1994.

However, in 1992 and 1993 a number of scientific publications appeared detailing studies of the role of nitric oxide in the relaxation of the smooth muscle of the penis. Such relaxation enables blood to fill the tissues, thereby causing an erection...

In its judgement, the Appeal Court said that several facts were known at the time the Viagra patent was filed. Not only had the structure of Viagra and its inhibitory effect on cGMP PDE(V) been elucidated, but it was also known that cGMP PDE(V) broke down the cGMP that contributed to an erection. It had also been suggested by this time that cGMP PDE(V) inhibitors might be useful in the treatment of impotence.

The Court considered that the difference between the content of these articles and the concept of claim 1 was obvious. In other words, anyone reading the articles would have realised that PDE(V) inhibitors were likely to be effective in the treatment of MED. "There was nothing inventive in trying them out for that purpose," it said.

However, the Court said that there was every reason to expect a good result in the treatment of MED by using cGMP PDE(V) selective inhibitors. The Court also rejected Pfizer's assertion that it discovered the potential of sildenafil in the treatment of MED through the observation of unwanted erections in patients taking part in trials of the drug's cardiovascular properties. In effect, it said the fact that the erections came as a surprise to Pfizer did not necessarily imply invention.

Philip W. Grubb

Patents for Chemicals, Pharmaceuticals and Biotechnology

Fundamentals of Global Law,
Practice and Strategy

⁵⁵
Oxford University Press, 2004 (4th edition, 511 pp.) ISBN 0-19-927378-2

Pascual Segura - Centre de Patents de la Universitat de Barcelona

PATENTS FOR CHEMICALS, PHARMACEUTICALS AND BIOTECHNOLOGY

FUNDAMENTALS OF GLOBAL LAW,
PRACTICE AND STRATEGY

Fourth Edition

by

PHILIP W. GRUBB

European Patent Attorney

BIBLIOTECA PARTICULAR DEL
Dr. PASCUAL SEGURA
Facultad de Química
Universidad de Barcelona

OXFORD
UNIVERSITY PRESS

CONTENTS

<i>List of Figures and Tables</i>	xi
<i>Table of Cases</i>	xii
<i>List of Abbreviations</i>	xxiv
PART I: INTRODUCTION AND BACKGROUND TO THE MODERN PATENT SYSTEM	
1 The Nature and Origins of Patent Rights	3
What is a Patent?	3
Early History in England	8
Early History in Continental Europe	10
Early History in America	12
The Consideration for the Grant of a Patent	14
2 Historical Developments in Industrialized Countries	15
United Kingdom: 1800–2004	16
USA: 1790–2002	20
Continental Europe	24
International Developments	25
TRIPs—A Major Step Forward	33
Summary	34
The Pendulum Swings Back?	36
3 Patents in Developing Countries	37
Level of Patent Protection	37
Transfer of Technology	39
New Developments in the 1980s and early 1990s	40
TRIPs Implementation—Changes to Patent Laws	41
The Convention on Biological Diversity (CBD)	49
Opposition to TRIPs	50
Summary	54
PART II: PATENT LAW AND PROCEDURE	
4 What can be Patented	57
The Requirements of the European Patent Convention and the Patents Act 1977	57
The Requirements of United States Law	67
Grace Periods	70
Special Categories of Inventions	72

5 Filing a Patent Application	75
Should an Application be Filed?	75
When to File	76
Where to File	80
The Foreign Filing Decision	84
Non-convention Filings	88
European Patent Applications	89
International Applications	91
Registration and Patents of Importation	92
6 Obtaining a Granted Patent—National Procedures	94
Types of Examination	94
Deferred Examination	98
Oppositions	100
Procedure in the United Kingdom	102
Procedure in the USA	108
7 Obtaining a Granted Patent—EPO and PCT Procedures	121
Procedure in the European Patent Office	121
Appeals in the EPO	136
PCT Procedure	141
8 Maintaining a Patent in Force and Extending the Patent Term	151
Patent Term	151
Renewal Fees	152
Extension of Term	155
Extensions to Compensate for Regulatory Delays	157
Working Requirements	163
Licences of Right	164
9 Enforcing Patent Rights	166
What Constitutes Infringement?	166
Infringement in the United Kingdom	167
Infringement in the USA	172
Procedure in the United Kingdom	177
Procedure in the USA	184
Procedure in Continental Europe	187
Procedure in Japan	189
10 Invalidity and Amendment of Granted Patents	190
Grounds of Invalidity in the United Kingdom	191
Former Grounds of Invalidity	192
New Grounds of Invalidity	194
Revocation Proceedings	194
Amendment of British Patents	196

Invalidity and Amendment in the USA	199
Invalidity and Amendment in the European Patent Office	202

PART III: PATENTABILITY OF INVENTIONS IN SPECIFIC TECHNICAL FIELDS

11 Chemical Inventions	211
Novel Compounds	211
Selection Inventions	214
Disclaimers	219
Compounds of Unknown Structure	220
Polymeric Compounds	222
New Physical Forms	223
New Synthetic Processes	224
Analogy Processes	225
New Compositions and Mixtures	226
New Uses and New Application Processes	227
12 Pharmaceutical Inventions	230
New Chemical Entities	230
Pharmaceutical Compositions	236
First Pharmaceutical Use	238
Second Pharmaceutical Use	239
Scope of SPC Protection	243
13 Biotechnological Inventions	245
What is Biotechnology?	246
Patents and Biotechnology	247
Microbiological Inventions	247
Recombinant DNA Technology	251
Monoclonal Antibody Technology	261
More Recent Technologies	265
14 Patenting of Genes, Plants, and Animals	269
Patents and Life	269
Human Genes	270
Transgenic Animals	272
Transgenic Plants	274
Patenting of Animals, Plants, and Human Cells	275
Morality Issues	281
Patents for Life—From Bacteria to Oncomice	283
Why are Patents Being Targeted?	285
15 Software-Related Inventions	287
Relevance of Software Inventions to Chemistry and Biotechnology	287

Patenting of Software-Related Inventions in the EPO	288
Patenting of Software-Related Inventions in the United Kingdom	293
Patenting of Software-Related Inventions in the USA	294
Business Method Patents	295
Chemical Applications— <i>In Silico</i> Screening	298
PART IV: PATENTING IN PRACTICE	
16 The Patent Practitioner and His Functions	303
The British Patent Profession	304
The Patent Profession in the USA	307
The Patent Profession in Other Countries	308
European Patent Attorneys	309
Patent Attorneys in Private Practice	312
Industrial Practice	314
The Job of the Patent Practitioner	315
17 Drafting the Patent Specification	320
Drafting the Scope	320
The Structure of the Patent Specification	322
Priority and Foreign Filing Texts	324
Background of the Invention and Prior Art	324
US Sufficiency Requirements	326
Sufficiency Requirements in the United Kingdom and the EPO	330
Sufficiency Requirements in Other Countries	332
Special Requirements for Biotech Inventions	333
Length of Text	334
18 Drafting the Claims	336
The Purpose and Nature of Patent Claims	336
Form of Claims	339
The Scope of the Claims	345
19 Prosecution of the Patent Application to Grant	349
Lack of Unity	349
Lack of Novelty	353
Lack of Inventive Step	357
Interviews with the Examiner	362
20 Patents and Information	364
The Increasing Volume of Patent Literature	364
Patents as a Source of Technical Information	365
Availability of Patents	367
Other Patent Information on the Internet	370
Legal Information Relevant to Patents	370
Patent Searching	371

PART V: COMMERCIAL EXPLOITATION OF PATENTS

21 Inventorship, Ownership, and Compensation	381
Inventorship in the United Kingdom	381
Inventorship in the EPO	384
Inventorship in the USA	385
Ownership	387
Compensation for Employee-inventors	392
The Right to Apply for a Patent and to be Granted a Patent	396
Co-ownership	397
Disputes as to Ownership	398
Registration and Transfer of Ownership	400
22 The Commercial Exploitation of Patents	401
Patents to Exclude the Competition—the Pharmaceutical Industry	401
Patents for Survival—the Biotechnology Industry	409
Patents as a Source of Royalty Income—Universities	412
Patents as Lottery Tickets—the Individual Inventors	416
Patents as Bargaining Chips—the Electronics Industry	416
23 How to Catch the Infringer—and how not to be Caught	419
From the Viewpoint of the Patentee	419
From the Viewpoint of the Potential Infringer	435
24 Patent Aspects of Licensing	440
Patent Conflict Licences	440
Technology Transfer Licences	441
The In-licensing Process	443
Out-licensing—Patent Strategy for the Licensor	447
Research Collaboration Agreements	450
Contract Research Agreements	452
Funding Agreements	453
Compound Purchase Agreements	453
Licence Contracts	453
25 Patents and Competition Law	458
Charges against the Patent System	458
Competition Law—United Kingdom	459
Competition Law—EU	460
Patent Licence Agreements in the EU	466
Competition Law—USA	472
<i>Glossary of Patent Terms and Jargon</i>	479
<i>Index</i>	491



La Organización Mundial de la Propiedad Intelectual (OMPI), en Ginebra, administra los Convenios de París y Berna, y el *Patent Cooperation Treaty, PCT*

WORLD INTELLECTUAL PROPERTY ORGANIZATION

ABOUT WIPO	IP SERVICES	PROGRAM ACTIVITIES	RESOURCES	NEWS & EVENTS
------------	-------------	--------------------	-----------	---------------

What is WIPO?
What is IP?
How WIPO works
Strategic Realignment
Members and Observers
Program and Budget
Treaties
Overview and Annual Reports
Oversight
Recruitment
Procurement



GATEWAY TO:

- Patents
- Trademarks
- Industrial Designs
- Geographical Indications
- Copyright
- Traditional Knowledge
- IP for Development
- Vision IP

RESOURCES FOR:

- Delegates
- Journalists
- Businesses
- Innovators
- Students

MOST REQUESTED:

- What is IP?
- Patent search
- Meetings
- Development Agenda
- Domain name decisions
- Treaties
- Member states
- SMF resources

- [ment Day with its first-ever Open Day on June 5, 2010](#)
- [Highlights Importance of Intellectual Property for Innovation](#)
- [ance Work On Traditional Knowledge, Folklore And](#)
- [Day 2010 – Innovation - Linking the World](#)
- [to Travel Advisory](#)
- [Resolution Services for TV Show Format Industry](#)



Cartoon - Copyright [Mdeo]



The WIPO Convention - Life Begins at 40!

DIRECTOR GENERAL



Francis Gurry
[Message](#)
[Speeches](#)
[Interviews](#)

Forthcoming Events

- [Standing Committee on Copyright and Related Rights](#) - June 21 to 24
- [WIPO Seminar on the Economics of Intellectual Property](#) - June 28
- [WIPO-WTO Colloquium for Teachers of Intellectual Property](#) - June 28 to July 9
- [Standing Committee on the Law of Trademarks, Industrial Designs and](#)

What is Intellectual Property? - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/about-ip/en/

Google Buscar

What is Intellectual Pro...

WIPO ABOUT WIPO

World Intellectual Property Organization

ABOUT WIPO IP SERVICES PROGRAM ACTIVITIES RESOURCES NEWS & EVENTS

Home > About WIPO > About Intellectual Property

What is Intellectual Property?

Intellectual property (IP) refers to creations of the mind: inventions, literary and artistic works, and symbols, names, images, and designs used in commerce.

IP is divided into two categories: Industrial property, which includes inventions (patents), trademarks, industrial designs, and geographic indications of source; and Copyright, which includes literary and artistic works such as novels, poems and plays, films, musical works, artistic works such as drawings, paintings, photographs and sculptures, and architectural designs. Rights related to copyright include those of performing artists in their performances, producers of phonograms in their recordings, and those of broadcasters in their radio and television programs. For an introduction to IP for non-specialists, refer to:

- [Understanding Copyright and Related Rights](#)
- [Understanding Industrial Property](#)
- [WIPO Intellectual Property Handbook](#) ← comprehensive introduction to the policy, law and use of IP)

The innovations and creative expressions of indigenous and local communities are also IP, yet because they are "traditional" they may not be fully protected by existing IP systems. Access to, and equitable benefit-sharing in, genetic resources also raise IP questions. Normative and capacity-building programs are underway at WIPO to develop balanced and appropriate legal and practical responses to these issues. For more information, refer to:

WIPO Intellectual Property Handbook: Policy, Law and Use - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/about-ip/en/iprm/

WIPO Intellectual Property Organization

ABOUT WIPO

World Intellectual Property Organization

ABOUT WIPO IP SERVICES PROGRAM ACTIVITIES RESOURCES NEWS & EVENTS

Home > About WIPO > About Intellectual Property > Intellectual Property Reading Material

WIPO Intellectual Property Handbook: Policy, Law and Use

WIPO Publication No.489

- Foreword
- Detailed Table of Contents
- Chapter 1 - Introduction
- Chapter 2 - Fields of Intellectual Property Protection
- Chapter 3 - The Role of Intellectual Property in Development and WIPO's Development Cooperation Program
- Chapter 4 - Enforcement of Intellectual Property Rights
- Chapter 5 - International Treaties and Conventions on Intellectual Property
- Chapter 6 - Administration and Teaching of Intellectual Property
- Chapter 7 - Technological and Legal Developments in Intellectual Property
- Bibliography
- Annex

Any information referred to in the text on the member States of WIPO treaties can be found by using the links indicated below

0FDB5A24d01 - Adobe Reader

Archivo Edición Ver Documento Herramientas Ventana Ayuda

1 / 146 105%

Buscar

Chapter 2

Fields of Intellectual Property Protection

- Patents**
 - Introduction
 - Conditions of Patentability
 - Drafting and Filing a Patent Application
 - Examination of a Patent Application
 - Infringement
 - Exploitation of the Patented Invention
 - Compulsory Licenses
 - Utility Models
- Copyright and Related Rights**
 - Introduction
 - Copyright Protection
 - Subject Matter of Copyright Protection
 - Rights Comprised in Copyright
 - Related Rights
 - Ownership of Copyright
 - Limitations on Copyright Protection
 - Piracy and Infringement

WIPO Intellectual Property Handbook: Policy, Law and Use - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/about-ip/en/iprm/

WIPO Intellectual Prope...

WORLD INTELLECTUAL PROPERTY ORGANIZATION

ABOUT WIPO IP SERVICES PROGRAM ACTIVITIES RESOURCES NEWS & EVENTS

Home > About WIPO > About Intellectual Property > Intellectual Property Reading Material

ABOUT INTELLECTUAL PROPERTY

What is Intellectual Property?

Inventions (Patents) ←

Trademarks

Industrial Designs

Geographical Indications

Copyright and related rights

Emerging issues in IP

IP in everyday life

RELATED LINKS

World IP Day

Women and IP

WIPO Intellectual Property Handbook: Policy, Law and Use

WIPO Publication No.489

- **Foreword** 
- **Detailed Table of Contents** 
- **Chapter 1** - Introduction 
- **Chapter 2** - Fields of Intellectual Property Protection 
- **Chapter 3** - The Role of Intellectual Property in Development and WIPO's Development Cooperation Program 
- **Chapter 4** - Enforcement of Intellectual Property Rights 
- **Chapter 5** - International Treaties and Conventions on Intellectual Property 
- **Chapter 6** - Administration and Teaching of Intellectual Property 
- **Chapter 7** - Technological and Legal Developments in Intellectual Property 
- **Bibliography** 
- **Annex** 

Any information referred to in the text on the member States of WIPO treaties can be found by using the links indicated below:

- [Status of Adherences to WIPO Administered Treaties](#)
- See also [texts of treaties administered by WIPO](#)

About Patents - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/patentscope/en/patents/

Google

Google Buscar

About Patents

PATENTSCOPE®

- About Patents
 - Meetings
 - PCT Resources
 - PCT Service Center
 - Database Search
 - Data Services
 - Publications
 - Projects & Programs
 - Patent Law
 - Priority Documents

RELATED LINKS

- Patent Classification: IPC
- Statistics
- Life Sciences
- WIPO Standards

E-NEWSLETTERS

- Subscription

About Patents

- » **General FAQs on Patents**
 - [What is a Patent?](#)
 - [What does a Patent do?](#)
 - [What kind of protection does a patent offer?](#)
 - [What rights does a patent owner have?](#)
 - [Why are patents necessary?](#)
 - [What role do patents play in everyday life?](#)
 - [What kinds of inventions can be protected?](#)
 - [Who grants patents?](#)
 - [How can a patent be obtained worldwide?](#)
 - [Where can I find patent information?](#)
 - [How can I find patent laws of various countries?](#)
 - [Can I obtain a patent on my software-related invention?](#)
 - [Can I discuss details of my invention with a potential investor before filing a patent application?](#)
- » [FAQs on Patents for SMEs](#)
- » [Patent Searches in Brief](#) 
- » [Guide on patents for business \[PDF\]](#)
- » [Patents and SMEs](#)

Patent Information in Brief - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/patentscope/en/data/patent_information.html

Google

Patent Information in Br...

PATENTSCOPE®

- About Patents
- PCT Resources
- PCT Service Center
- Database Search
- Data Services
- Publications
- Projects & Programs
- Patent Law
- Priority Documents

RELATED LINKS

- Patent Classification: IPC
- Statistics
- Life Sciences
- WIPO Standards

E-NEWSLETTERS

- Subscription

Patent Information in Brief

FAQs on Patent Information

- [What is patent information?](#)
- [What is the volume of patent information?](#)
- [Why search patent information?](#)
- [What are the characteristics of patent documents?](#)
- [Who are the main user groups of patent information?](#)

Various types of searches using patent documentation

- [Pre-Application Searches \(PAS\)](#)
- [State-of-the-Art Searches](#)
- [Novelty Searches](#)
- [Patentability or Validity Searches](#)
- [Name Searches](#)
- [Technological Activity Searches](#)
- [Infringement Searches](#)
- [Patent Family Searches](#)
- [Legal Status Searches](#)

» FAQs on Patent Information

What is patent information?

The screenshot shows a Mozilla Firefox browser window with the title "Patent Information in Brief - Mozilla Firefox". The address bar contains the URL "http://www.wipo.int/patentscope/en/data/patent_information.html#". The page content is as follows:

What are the characteristics of patent documents?

Hereafter are given brief descriptions of specific characteristics of patent documents, which make them extremely useful sources of technological information, with some clear advantages over other sources of information.

Description, Claims, Drawings

Patent documents generally have a fairly uniform structure that facilitates the extracting of information: the claims give the essence of what is new; the description gives the background to the invention (what was known before the invention, i.e., the "prior art"), and defines the difference between the pre-existent technology and what the invention contributes, as a new matter, as a step forward, to technology development; often patent documents contain also drawings, that illustrate the invention that is claimed.

Technological information is disclosed by describing the inventions in accordance with the requirements of the applicable patent law and by indicating the claimed novelty and inventiveness by reference to the existing state of the art. Certain patent documents are published together with a search report showing a series of references found at the occasion of a documentary search made to establish in a first instance the level of novelty of the claimed invention.

Abstracts

Many patent documents contain an abstract. Abstracts allow a general idea to be formed of the contents of the document within a few minutes, and in any case a much shorter time than would be required to read the full text of the patent document.

Classification

Patent documents bear "classification symbols" which facilitate very much finding and extracting relevant information from them. For the purposes of maintaining search files and performing searches for the state of the art, patent offices classify patent documents according to the field or fields of technology to which their contents relate. Although several classification systems exist, today the International Patent Classification (IPC), which was established by an intergovernmental agreement concluded more than 30 years ago and administered by WIPO, is the most widely applied by all the major industrial property offices. The main part of the high cost of processing and classifying patent documents for building up search files, and of keeping the classification system up to date, is borne directly by the



Encouraging Creativity and Innovation

العربي | 中文 | Español | Français | Русский

 Search

Contact us | Accessibility | Site map

WORLD INTELLECTUAL PROPERTY ORGANIZATION

ABOUT WIPO IP SERVICES PROGRAM ACTIVITIES RESOURCES NEWS & EVENTS

GATEWAY TO:

- Patents
- Trademarks
- Industrial Designs
- Geographical Indications
- Copyright
- Traditional Knowledge
- IP for Development
- Vision IP

RESOURCES FOR:

- Delegates
- Journalists
- Businesses
- Innovators
- Students

MOST REQUESTED:

- What is IP?
- Patent search
- Meetings
- Development Agenda
- Domain name decisions
- Treaties
- Member states
- SMF resources

New at WIPO

- WIPO Marks World Environment Day
- WIPO Director General Highlights Key Areas of Work and Technology Transfer
- WIPO Member States Advance Genetic Resources
- WIPO Unveils New Logo
- World Intellectual Property Day
- Rescheduled Meetings due to COVID-19
- WIPO to Provide Dispute Resolution Services

Developing laws and standards
IP for Development
Copyright issues
Traditional Knowledge, Folklore, Genetic Resources
Cooperation with Certain Countries in Europe and Asia
Global IP Infrastructure
Small and Medium-sized Enterprises
WIPO Academy
Public Outreach
Enforcement of IP Rights

...y on June 5, 2010
 ...erty for Innovation
 ... Folklore And
 ... World
 ...nat Industry



Cartoon - Copyright [Video]



The WIPO Convention - Life Begins at 40!

DIRECTOR GENERAL



Francis Gurry
 Message
 Speeches
 Interviews

Forthcoming Events

- Standing Committee on Copyright and Related Rights - June 21 to 24
- WIPO Seminar on the Economics of Intellectual Property - June 28
- WIPO-WTO Colloquium for Teachers of Intellectual Property - June 28 to July 9
- Standing Committee on the Law of Trademarks, Industrial Designs and

WIPO Worldwide Academy - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/academy/en/

WIPO Worldwide Academy

WIPO WORLDWIDE ACADEMY

- Overview
- News
- Events
- Courses
- Teaching IP
- Research
- Global Network of IP Academies (GNIPA)
- Partnerships
- Links
- Contact us
- Site index

RELATED LINKS

- Library
- Collection of Laws (CLEA)

WIPO Worldwide Academy

The WIPO Worldwide Academy was founded in March 1998 in response to demand for knowledge and skills in intellectual property (IP). It serves as a center of excellence in teaching, training and research in IP. Its programs cater to different target audiences - inventors and creators, business managers and IP professionals, policy makers and government officials of IP institutions, diplomats and representatives, students and teachers of intellectual property and the civil society.

Its objectives are achieved through five core programs - professional training, distance learning, policy development, teaching and research, education and degree. The tailor-made programs, including its distance learning with more than 87,000 participants since its inception in 1999, benefit large numbers of people from all walks of life.

The Academy seeks to continuously stay innovative by offering new programs to keep up with the ever-changing IP landscape. It also aims to promote international cooperation for enhancing IP human capital through global networking with stakeholders and partners.

- [Global Network on Intellectual Property \(IP\) Academies](#)
- [Conferences](#)
- [Video clips of Academy Events](#)

Academy Programs:

- [Distance Learning](#)
- [Professional Development](#)
- [Education & Degree](#)
- [Summer School on IP](#)

ANNOUNCEMENTS:

- New** 4th meeting of the Global Network on IP Academies (GNIPA), Seoul, ROK, August 24 to 26, 2010
- New** WIPO Summer Schools on Intellectual Property - 2010

DL Objectives, info, methodology - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/academy/en/courses/distance_learning/index.f

DL Objectives, info, met...

عربي | 中文 | Español | Français | Русский

WIPO PROGRAM ACTIVITIES

WORLD INTELLECTUAL PROPERTY ORGANIZATION

ABOUT WIPO IP SERVICES PROGRAM ACTIVITIES RESOURCES NEWS & EVENTS

Home > Program Activities > WIPO Worldwide Academy > Courses

WIPO WORLDWIDE ACADEMY

- Overview
- News
- Events
- Courses
- Teaching IP
- Research
- Global Network of IP Academies (GNIPA)
- Partnerships
- Links
- Contact us
- Site index

RELATED LINKS

- Library
- Collection of Laws (CLEA)

Distance Learning Catalog of Courses

The courses offered by the **Distance Learning program** of the Academy are available in the following languages:

[Arabic](#), [Chinese](#), [English](#), [French](#), [Portuguese](#), [Russian](#) and [Spanish](#)

Objectives

The WIPO Worldwide Academy uses distance learning as an alternative and a complement to traditional training methods in order to make course materials accessible to large audiences worldwide. Distance learning courses are delivered primarily via the Internet and offer new teaching methodologies, specially-designed course materials, evaluation tools, and tailored means of delivery. Where appropriate, videoconferencing sessions are organized to simulate an academic environment by linking remote sites. Courses are specifically adapted to allow student-teacher interaction, student tests, course monitoring, and on-line registration and evaluation systems.

The greatest advantage of distance learning as a study methodology is that its reach is not confined by such constraints as geographical location and time. Thus, any registered student, anywhere in the world, can benefit from the WIPO Worldwide Academy's distance learning program at a time and place convenient to him/her.

This has revolutionized the way in which we both teach and learn.

Through distance learning, the Academy strives to increase the educational opportunities of a broad spectrum of beneficiaries worldwide, using this website as a delivery platform.

Distance Learning Program Course Calendar 2010 (subject to change)

Primers:

Open Registration:

- DL-001 Primer on Intellectual Property
- 101PCT Introduction to the Patent Cooperation Treaty

➤ Register online at any time to take these courses

General Courses:

Session 1:

Course Dates	Course Title
March 1 to April 15, 2010 Exam : April 16 to 18	DL-101 General Course on Intellectual Property

➤ Register online from December 1, 2009 to February 18, 2010

Session 2:

Course Dates	Course Title
October 1 to November 15 Exam : November 16 to 18	DL-101 General Course on Intellectual Property

➤ Register online from July 1 to September 20, 2010

Advanced Courses:

Session 1:

Course Dates	Course Title
March 9 to May 17	DL-301 Patent
March 10 to May 18	DL-302 Trademarks, Industrial Designs and Geographical Indications
March 16 to April 27	DL-317 Arbitration
March 11 to May 19	DL-318 Patent Information Search
March 11 to May 19	DL-320 Basics of Patent Drafting
July 7 to September 15	New DL-450 Intellectual Property Management *

- Register online from December 1, 2009 to February 21, 2010
- * Register for DL-450 until March 19, 2010

Session 2:

Course Dates	Course Title
September 16 to November 25	DL-201 Copyright and Related Rights
September 16 to October 28	DL-202 Electronic Commerce and Intellectual Property
September 16 to November 25	DL-204 Biotechnology and Intellectual Property

- Register online from June 21 to July 31, 2010

➤➤ For further information and to register online, please visit <http://academy.wipo.int> <<

Updated: 17.05.2010

DL-301E Patents

Summary: This advanced course is intended to explain the basic principles of patents, their economic impact, the process of patenting, describe technology transfer, patent pool and the traditional use of patents by centers of knowledge such as universities. It covers the important aspects of the patent document used in the enforcement of patent rights and the various aspects of enforcement.

Tutored: Yes **Duration:** 100 hours **Cost:** [Fee List](#)

Next Session: March 9 to May 17, 2010

Enrollment: December 1, 2009 to February 18, 2010

Course Administrator: DL301e.academy@wipo.int

[More details](#)

[Enroll Now](#)

[Log On](#)

Advanced Courses Fees

Currency	Amount	Category
US dollar	400	standard fee
US dollar	250	student fee

DL-320E Basics of Patent Drafting

Summary: The intention of this advanced distance learning course on the basics of patent drafting is to introduce you to, and illustrate the concepts, of patent drafting. Some practical exercises are proposed with enough background and description to help you gain confidence to form a credible set of claims.

Tutored: Yes **Duration:** 100 hours **Cost:** [Fee List](#)

Next Session: March 11 to May 19, 2010

Enrollment: December 1, 2009 to February 18, 2010

Course Administrator: DL320e.academy@wipo.int

[More details](#)

[Enroll Now](#)

[Log On](#)

[Email](#)

WIPO Worldwide Academy - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.wipo.int/academy/en/

WIPO Worldwide Academy

WIPO WORLDWIDE ACADEMY

- Overview
- News
- Events
- Courses
- Teaching IP
- Research
- Global Network of IP Academies (GNIPA)
- Partnerships
- Links
- Contact us
- Site index

RELATED LINKS

- Library
- Collection of Laws (CLEA)

WIPO Worldwide Academy

The WIPO Worldwide Academy was founded in March 1998 in response to demand for knowledge and skills in intellectual property (IP). It serves as a center of excellence in teaching, training and research in IP. Its programs cater to different target audiences - inventors and creators, business managers and IP professionals, policy makers and government officials of IP institutions, diplomats and representatives, students and teachers of intellectual property and the civil society.

Its objectives are achieved through five core programs - professional training, distance learning, policy development, teaching and research, education and degree. The tailor-made programs, including its distance learning with more than 87,000 participants since its inception in 1999, benefit large numbers of people from all walks of life.

The Academy seeks to continuously stay innovative by offering new programs to keep up with the ever-changing IP landscape. It also aims to promote international cooperation for enhancing IP human capital through global networking with stakeholders and partners.

- [Global Network on Intellectual Property \(IP\) Academies](#)
- [Conferences](#)
- [Video clips of Academy Events](#)

Academy Programs:

- [Distance Learning](#)
- [Professional Development](#)
- [Education & Degree](#)
- [Summer School on IP](#)

ANNOUNCEMENTS:

- New** 4th meeting of the Global Network on IP Academies (GNIPA), Seoul, ROK, August 24 to 26, 2010
- New** WIPO Summer Schools on Intellectual Property - 2010



Present Members

List of present members of the Global Network:

COUNTRY	INSTITUTION	URL
Australia	Intellectual Property Research Institute of Australia (IPRIA)	www.ipria.org
Brazil	National Institute of Industrial Property of Brazil (INPI)	www.inpi.gov.br
Bulgaria	Centre for Intellectual Property of the University of National and World Economy	www.unwe.acad.bg
China	State Intellectual Property Office of China (SIPO)	www.sipo.gov.cn
Croatia	State Intellectual Property Office of Croatia (SIPO)	www.dziv.hr
Cuba	Industrial Property Office of Cuba (OCPI)	www.ocpi.cu
Japan	National Center for Industrial Property Information and Training	www.inpit.go.jp
<hr style="border-top: 1px dashed black;"/>		
United States of America	United States Patent and Trademark Office Global Intellectual Property Academy	http://www.uspto.gov/web/offices/dcom/olia/training_history.htm

ACRONYM	INSTITUTION	URL
ARIPO	African Regional Intellectual Property Organization	www.aripo.wipo.net
EPO	European Patent Academy	www.epo.org/about-us/office/academy.html 
OAPI	Intellectual Property Training Center Denis Ekani	www.oapi.wipo.net
WWA	WIPO Worldwide Academy	www.wipo.int/academy

EPO - European Patent Academy - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.epo.org/about-us/office/academy.html

Search Enter search term Accessibility Contact Help Sitemap | Deutsch English Français

Patents **About us** **Topics**

European Patent Organisation **The Office** Boards of appeal EPO events Publications Press Jobs Tenders European Patent N

Mission and vision
 Activities
 Office film
 President
 Management committee
 Official holidays in 2010
 International relations
European Patent Academy
 Programme areas
 Organs
 Partners
 Annual reports
 Statistics
 History

Home → About us → The Office → European Patent Academy

European Patent Academy

"Promoting and supporting education and training in patent-related intellectual property"

The European Patent Academy ensures the overall co-ordination of the external education and training activities of the European Patent Office.

The mandate of the European Patent Academy, based at the European Patent Office in Munich, reflects the need to improve patent-related intellectual property training and education structures in Europe.



Programme areas

The Academy's activities are divided into five programme areas, aimed at different target

e-learning ←

Consult e-learning modules online in the Learning area.

EPO e-learning - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

EPO e-learning | EPO homepage | Terms of use

e-learning

[Home](#)
[Public modules](#) 
[Online help](#)

e-learning

The EPO's learning management system (LMS) is an e-learning platform which provides access to materials covering a wide range of patent-related topics. Since you can access the modules and courses at a time and pace that suits you, the LMS is a cost-effective and flexible alternative to traditional classroom-based learning.

On the left you will find a link to our open-access **public modules** accessible without prior registration. These modules cover everything from the European patent system to patent searching and innovation in business. To view the modules on offer, simply click on the link in the top left-hand corner of this page.

Login:

Login name

Password

To receive information about updates and new modules/courses, please click on the Register button (below left) and set up a user profile with your own login name and password. You can also use this profile to manage (i.e. bookmark) your public modules.

In addition to the LMS, the European Patent Academy, the EPO's external training and education arm, also offers users a **patent event search** function (on the right) which you can use to find out about patent-related events around Europe, including courses run by the European Patent Academy.

When you sign up for any of the e-learning courses organised by the Academy you will be provided with login data which will allow you to access the course in the LMS. In addition to the specific e-learning materials relating to the course you have chosen, the LMS will allow you to participate in discussion forums with fellow participants and tutors and an

Contact us

- We would be pleased to receive any feedback or comments that you may have on either the Learning Management System, or the courseware offered. Please contact the

European Patent Academy

- If you are interested in EQE training activities and if you have not yet received your login details, please contact the

[Academy Forum](#)

Patent Event Search

Calendar of patent-related events

[Conferences, seminars, courses and other patent-related events](#)

EQE Forum



e-learning

- Home
- Public modules**
- Online help

Login:

Login name

Password

Note: Your log in was not successful. For detailed information please click [HERE](#)

Public modules

Overview | Search

- Structure**
- [-] [European Patent System](#)
 - [-] **European Patent System**
 - [-] [Biotechnology](#)
 - [-] [Revision of the European Patent Convention \(EPC 2000\)](#)
 - [-] [Computer-implemented inventions](#)
 - [+] [Searching and documentation](#)
 - [+] [IP, innovation and business](#)
 - [-] [EPO Online Services - the way to do IP](#)
 - [+] [Special topics](#)
 - [+] [European Patent Academy](#)
 - [-] [General usage information](#)
 - [-] [How to Get a European Patent](#)

European Patent System		
Contents	Data	Action
Basic principles of unity of invention of a European patent application Basic module European Patent System	English (GB)	<input type="button" value="▶"/>
Clarity of a European patent application Basic module European Patent System	English (GB)	<input type="button" value="▶"/>
Examining the description and claims of a European patent application Basic module European Patent System	English (GB)	<input type="button" value="▶"/>
Requirement and concept of novelty as defined in the EPC Basic module European Patent System	English (GB)	<input type="button" value="▶"/>
Theory of inventive step and the problem-solution approach of a European patent application Basic module European Patent System	English (GB)	<input type="button" value="▶"/>
The extended European Search Report Charlotte Schmidt, Principal Examiner, Practise and Procedure, EPO	English (GB)	<input type="button" value="▶"/>



Unity of Invention

Service provided by the European Patent Academy,
with the kind support of the internal training department L&D of the European Patent Office



Unity of Invention - Mozilla Firefox

epo.org https://e-learning.epo.org/data/wbt/decompressed/basicmodules_unityofinvention_published_558087/player.html

Unity of Invention (04:22 / 09:39) EXIT




Outline Thumbnails Notes Search

- 1. Unity of Invention
- 2. Overview
- 3. Principles of unity
- 4. Article 82 EPC
- 5. Rule 44(1) EPC
 - 6. Rule 44(1) EPC
- 7. Rule 44(2) EPC
- 8. Lack of unity a priori and a posteriori
- 9. Assessing unity of invention
- 10. Single general inventive concept approach
 - 11. Example
- 12. Special technical feature approach
- 13. Corresponding special technical features
- 16. Common situations
- 17. Unitary combination of categories
- 19. Not unitary combination of categories
- 20. Self Evaluation
- 21. Quiz Questions
- 22. Thank you for your attention!

Assessing unity of invention

- Single general inventive concept approach
- Special technical feature approach



20. Self Evaluation

21. Quiz Questions

[Article 82 EPC](#)
[Rule 44\(1\) EPC](#)

SLIDE 9 OF 22 CLICK NEXT TO ADVANCE 00:51 / 00:51

Novelty

EPO epo.org https://e-learning.epo.org/data/wbt/decompressed/basicmodules_novelty_published_

Novelty (00:43 / 12:35)



Outline Thumbnails Notes Search

- ▼ 1. Novelty
- 2. Overview
- ▶ 3. Definition - Article 52(1)
- ▶ 10. Combining Disclosures
- ▶ 12. Claim analysis (construal)
- 16. Equivalents
- ▶ 17. Common Situations
- 20. Ranges of values
- ▶ 21. Selection Inventions
- 24. Self Evaluation
- 25. Quiz Questions
- 26. Thank you for your attention!

Overview

- The requirement of novelty
- The meaning of *novelty*

- Construal of claims
 - Implicit features
 - Equivalent features

- Common situations
 - Generic vs. specific disclosures
 - Selection inventions
 - Overlapping ranges
 - Selection from two or more lists





e-learning

- Home
- Public modules**
- Online help

Login:

Login name

Password

Note: Your log in was not successful. For detailed information please click [HERE](#)

Public modules

- Overview
- Search**

- Structure**
- European Patent System
 - Searching and documentation**
 - Patent information - general
 - The European Patent Classification
 - esp@cenet
 - "Search matters" seminar
 - IP, innovation and business
 - EPO Online Services - the way to do IP
 - Special topics
 - European Patent Academy
 - General useage information
 - How to Get a European Patent

Searching and documentation

Contents	Data	Action
Patent information tour	English (GB)	<input type="button" value="▶"/>
Introduction to the European Patent Classification Roberto Iasevoli	English (GB)	<input type="button" value="▶"/>
IPC and ECLA - comprehensive search and retrieval Heiko Wongel Search Matters 2007	English (GB)	<input type="button" value="▶"/>
esp@cenet assistant	English (GB)	<input type="button" value="▶"/>
esp@cenet - freely accessible patent database and professional sources Paul Schwander	English (GB)	<input type="button" value="▶"/>
L1: EPO documentation strategy John Bambridge Search Matters 2009	English (GB)	<input type="button" value="▶"/>



Welcome to the **esp@cenet® assistant!**



Topics

- T1 Getting Started
- T2 The Results List
- T3 Searching & Criteria
- T4 Classification
- T5 Search Strategies
- T6 Patent Documents
- T7 Tips & Tricks
- T8 New in esp@cenet

esp@cenet® assistant

[Deutsch](#) | [English](#) | [Français](#)

Welcome

This interactive training course offers everything you need to use esp@cenet efficiently: **search strategies, power tips, background information** and more...

How to start...

A Guided Tour through esp@cenet

➔ **The Guided Tour:** An initial overview in 8 short chapters (lasting a total of 17 minutes)

e-learning

Home

Public modules

Online help

Login:

Login name

Password

Note: Your log in was not successful. For detailed information please click [HERE](#)

Login

Forgot your password?

Register

Public modules

Overview | Search

Add to Bookmarks | Print preview

Structure	How to Get a European Patent		
	Contents	Data	Action
European Patent System			
Searching and documentation			
IP, innovation and business			
EPO Online Services - the way to do IP			
Special topics			
Patenting in China			
European Patent Academy			
General usage information			
How to Get a European Patent	How to get a European Patent Module 1A - General	English (GB)	
	How to get a European Patent Module 1B - Patentability	English (GB)	
	How to get a European Patent Module 1C - Preparing and filing a European patent application (Part a)	English (GB)	
	How to get a European Patent Module 1C - Preparing and filing a European Patent Application (Part b)	English (GB)	
	How to get a European Patent Module 1C - Preparing and filing a European patent application (Part c)	English (GB)	
	How to get a European Patent Module 1D - The European patent grant procedure (Part a)	English (GB)	
	How to get a European Patent Module 1D - The European patent grant procedure (Part b)	English (GB)	



How to get a European Patent Guide for applicants

Module 1 - General

European Patent Academy



How to get a European Patent Part 1A - Mozilla Firefox

epo.org https://e-learning.epo.org/data/wbt/decompressed/htgaep_1a_571412/HTGAEP_1A/player.html

How to get a European Patent Part 1A (01:04 / 82:39) EXIT



Outline Thumbnails Notes Search

- 1. How to get a European Patent
- 2. Welcome**
- 3. Introduction
- 8. Nature and purpose of the EPC
- 14. Relationship to other international conventions
- 18. Choosing a route
- 24. Question 6
- 35. Extending European patents to non-EPC states
- 37. Summary

Welcome

to the web-based training of the **European Patent Academy** on

How to get a European Patent



Content overview

- Additional resources
- Nature and purpose of the European Patent Convention
- Relationship to other international conventions
- Choosing a route: national, European or international
- Extending European patents to non-EPC states

SLIDE 2 OF 37 CLICK NEXT TO ADVANCE 00:59 / 00:59



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

**Headquarters Munich
PschorrHöfe**



**Headquarters Munich
Isar building**



Branch at The Hague

Vienna sub-office



Berlin sub-office

El 80-85% de las patentes (no modelos utilidad) llegan a España por la vía europea (concedidas tras examen en la Oficina Europea de Patentes)

EPO - Home - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

http://www.epo.org/

EPO e-learning EUROPEAN PATENT CON... EPO - Home

Search Enter search term Accessibility Contact Help Sitemap | Deutsch English Français

Europäisches Patentamt
European Patent Office
Office européen des brevets

Amendments to the Implementing Regulations as of 1.4.2010

[Go to page](#)

How to apply for a patent

A simple guide to the grant procedure

[More information](#)



Patents
About us
Topics

News

12.5.2010
EBoA confirms EPO approach to computer programs
Today the Enlarged Board of Appeal of the EPO handed down its opinion on referral G3/08, taking the opportunity to set out and confirm the approach of the EPO regarding the patentability of computer programs under the European Patent Convention (EPC).



1.5.2010
Welcome, Albania!
Albania becomes the 37th member state of the EPO. European patents are now valid in up to 40 countries and reach a market of about 570 million people.

Updates

25.5.2010
Decision of the President of the European Patent Office dated 11 May 2010 concerning the entrustment to non-examining staff of certain duties normally the responsibility of the examining or opposition divisions

21.5.2010
Enlarged Board of Appeal: new petition for review (R 6/10 and R 7/10)

18.5.2010
Asian patent information: Chinese patent monitoring services now available

17.5.2010
The Administrative Council's calendar has been

Quick access

Grant procedure

Please select

Online services: filing, monitoring, fees

Patent information

Please select

esp@cenet: search 60 million patent documents online

Law

Please select

EPO - Patents - Mozilla Firefox

Archivo Editar Ver Historial Marcadores Herramientas Ayuda

[EPO](#) [http://www.epo.org/patents.html](#)

[Google](#)

[EPO e-learning](#)
[EUROPEAN PATENT CON...](#)
[EPO - Patents](#)

Search
[Accessibility](#) [Contact](#) [Help](#) [Sitemap](#) |
 [Deutsch](#) [English](#) [Français](#)

Patents | [About us](#) | [Topics](#)

[Updates](#) | [Grant procedure](#) | [Patent information](#) | [Law](#) | [Appeals](#) | [Learning](#)

[Home](#) → [Patents](#)

Patents

All the tools and information that inventors, lawyers, engineers, scientists, researchers and enterprises need to conduct business with the European Patent Office.

Guidelines for Examination

Edition 2010

[Order the Guidelines for Examination 2010](#)

EPO Newsletter

Subscribe to our e-mail newsletter to keep abreast of the latest news and announcements.

[Subscribe now](#)

Latest updates

25.5.2010
[Decision of the President of the European Patent Office dated 11 May 2010 concerning the entrustment to non-examining staff of certain duties normally the responsibility of the examining or opposition divisions](#)

21.5.2010
[Enlarged Board of Appeal: new petition for review \(R 6/10 and R 7/10\)](#)

20.5.2010
[Update on US assignments in the INPADOC legal status database](#)

[Updates archive](#) | [RSS: all updates](#)

Upcoming educational events

27.5.2010 | [Virtual classroom, Online Monthly online patent information newsflash](#)

27.5.2010 | [Brussels, Belgium Second IP pre-diagnosis follow-up workshop](#)

31.5.2010 | [The Hague, Netherlands EpogueNet functionalities and use \(standard\)](#)

Find seminars and other educational events offered by the EPO or consult e-learning modules online in the [Learning area](#).

Patent information

Quick access to documents, databases and services.

Update on OS assignments in the INPADOC legal status database

Updates archive | RSS: all updates

Grant procedure

How to apply for a patent: a simple guide to the grant procedure

About patents

Filing an application

Find a professional representative

Oral proceedings

Online Services: filing, monitoring, fees

Appeals

Search the database of board of appeal decisions

Recent decisions

Enlarged Board of Appeal

More

Patent information

Quick access to documents, databases and services.

Please select [dropdown] Go

Legal texts

Please select [dropdown] Go

- Please select
- European Patent Convention
- Official Journal
- Guidelines for Examination
- London Agreement
- National law relating to the EPC
- Case Law of the Boards of Appeal
- European National Patent Decisions Report
- Archive

Firefox Mozilla Firefox

http://www.epo.org/patents.html

EUROPEAN PATENT CON... EPO - Patents

Update on US assignments in the INPADOC legal status database

Updates archive | RSS: all updates

Patent information

Quick access to documents, databases and services.

Grant procedure

[How to apply for a patent: a simple guide to the grant procedure](#)

[About patents](#)

[Filing an application](#)

[Find a professional representative](#)

[Oral proceedings](#)

[Online Services: filing, monitoring, fees](#)

Appeals

[Search the database of board of appeal decisions](#)

[Recent decisions](#)

[Enlarged Board of Appeal](#)

[More](#)

Please select

- Please select
- About patent information
- European patent documents
- Free databases
- Subscription databases
- Raw data resources (INPADOC)
- Asian patent information
- Business use of patent information
- Patent information centres (PATLIB)
- IPC
- About EPO data
- Ordering and prices

How to apply for a European patent

A step-by-step guide to the grant procedure

This guide provides basic information about the steps involved in the European patent granting procedure. Before applying for a patent, you should make sure that this is the best option for your invention. If you are unsure, please refer to the "[About patents](#)" page and the [FAQ](#), which are linked to from step 1.

1 Before applying for a European patent

Make sure that you know the answer to these questions before you apply:

- What is an invention?
- What is a patent?
- What is the purpose of a patent?
- What are the advantages of a European patent?
- How can I get patent protection?
- How can I get a European patent?
- [About patents](#)
- [FAQ](#)
- [The seven deadly sins of the inventor](#)
- [European Patent Convention](#)
- [EPO Online Services](#)
- [esp@cenet](#) (patent information database)
- [Patent information](#)
- [Glossary](#)

2 Application

There are different routes to patent protection and the best route for you will depend on your invention and the markets your company operates in. The European Patent Office accepts applications under the European Patent Convention (EPC) and the Patent Cooperation Treaty (PCT). If you are seeking protection in only a few countries, it may be best to apply direct for a national patent to each of the national offices.

A European patent application consists of:

- a request for grant
- a description of the invention
- claims
- drawings (if any)
- an abstract.

- Grant procedure
- European applications
- International applications
- National applications
- Fees and expenses
- Guide for applicants - Part 1 
- Guide for applicants - Part 2
- EPO Online Services
- Find a professional representative
- PatentIn software (for filing of sequence listings)

Guide for applicants. Part 1

How to get a European patent

The "Guide for applicants" has been designed to provide inventors, companies and their representatives with an outline of the procedure involved in applying for a European patent, offering practical advice to smooth the way through the various stages.

The Guide cannot go into the details or specific issues of the European patent grant procedure, and it does not constitute an official commentary on the European Patent Convention (EPC).

If you need more detailed information, you are advised to consult the Guidelines for Examination in the European Patent Office, a comprehensive guide to every stage of the grant procedure and to EPO practice.

Order "Guide for applicants. Part 1"

Order

[Guide for applicants. Part 1](#)

Online

[e-learning modules \(under "Public modules"\)](#) (PDF, 54 KB)

Download

[Guide for applicants. Part 1](#) (PDF, 1.45 MB) 

[Guide for applicants. Part 1](#) (ZIP, 1.25 MB)

430C65AFd01 - Adobe Reader

Archivo Edición Ver Documento Herramientas Ventana Ayuda

1 / 127 75%

Buscar

Marcadores

- How to get a European patent
 - Contents
 - Foreword
 - A. General
 - I. Introduction
 - II. Nature and purpose of the European
 - III. Relationship to other international
 - IV. Choosing a route: national,

How to get a European patent

Guide for applicants

Part 1

May 2010
(13th edition)
Updated to 1.5.2010

3 Filing and formalities examination

The first step in the European patent granting procedure is the examination on filing. This involves checking whether all the necessary information and documentation has been provided, so that the application can be accorded a filing date.

- [Fees and expenses](#)
- [Guide for applicants - Part 1](#)
- [Guide for applicants - Part 2](#)

4 Search

While the formalities examination is being carried out, a European search report is drawn up, listing all the documents available to the Office that may be relevant to assessing novelty and inventive step. The search report is based on the patent claims but also takes into account the description and any drawings. Immediately after it has been drawn up, the search report is sent to the applicant together with a copy of any cited documents and an initial opinion as to whether the claimed invention and the application meet the requirements of the

- [Guidelines for Examination , Part B](#) 
- [European Patent Convention](#)



Patents About us Topics

Updates Grant procedure Patent information Law Appeals Learning

Legal texts

- European Patent Convention
 - Official Journal
 - Guidelines for Examination**
 - London Agreement
 - National law relating to the EPC
 - Case Law of the Boards of Appeal
 - European National Patent Decisions Report
 - Archive
- Legislative initiatives

Home → Patents → Law → Legal texts → Guidelines for Examination

Guidelines for Examination in the European Patent Office (status April 2010)

1. By decision of the President of the EPO dated 19 November 2009, the Guidelines for Examination have been amended pursuant to [Article 10\(2\) EPC](#). The amendments are being published in the form of a complete "April 2010" edition of the Guidelines. These have been revised following consultation with the Standing Advisory Committee before the EPO (SACEPO). The amended Guidelines will apply as from 1 April 2010.
2. The updated Guidelines for Examination are published in all three EPO languages on the EPO website and are available for downloading free of charge. They will also be issued in paper form.
3. The English draft of these Guidelines was published on the EPO website in November 2009 in order to accommodate public interest in gaining the earliest possible access to information on the future amendments.
4. It should be noted that the "April 2010" edition of the Guidelines for Examination is the only valid official version, and supersedes the "April 2009"

Order

- [Order the Guidelines for Examination 2010](#)
- [Order the ESPACE Legal DVD](#)

Online

- [HTML version](#)

Download

- [Complete guidelines](#) (PDF, 4.8 MB)
- [General part](#) (PDF, 120 KB)
- [Part A](#) (PDF, 830 KB)
- [Part B](#) (PDF, 500 KB)
- [Part C](#) (PDF, 1 MB) ←
- [Part D](#) (PDF, 400 KB)

Print version

Subscriptions

[Official Journal of the EPO](#)

Grant procedure

[Fees, expenses and prices](#)

Legislative initiatives

[London Agreement](#)

[See all legislative initiatives](#)

Search

The [database of professional representatives before the EPO](#)

Boards of appeal

Consult the [database](#) of the boards of appeal decisions

Order

F22718F9d01 - Adobe Reader

Archivo Edición Ver Documento Herramientas Ventana Ayuda

5 / 175 81,5%

Buscar

Marcadores

- Notice from the European Patent Office
- Part C Guidelines for Substantive Examination**
- Chapter I Introduction
- Chapter II Content of a European patent application
- Chapter III Claims
- Chapter IV Patentability
- Chapter V Priority
- Chapter VI Examination

April 2010 Part C - Contents a

CONTENTS

Chapter I – Introduction		I-1
<hr/>		
1.	General remark	I-1
2.	Work of an examiner	I-1
3.	Overview	I-1
<hr/>		
Chapter II – Content of a European patent application (other than claims)		II-1
<hr/>		
1.	General	II-1
2.	Abstract	II-1
3.	Request for grant – the title	II-1
<hr/>		
4.	Description	II-2
4.1	General remarks	II-2
4.2	Technical field	II-2
4.3	Background art	II-2
4.4	Irrelevant matter	II-3
4.5	Technical problem and its solution	II-4
4.6	Rule 42(1)(c) vs. Art. 52(1)	II-4
4.7	Drawings	II-4
4.8	Reference signs	II-5
4.9	Sufficiency of disclosure	II-5
4.10	Art. 83 vs. Art. 123(2)	II-6
4.11	Insufficient disclosure	II-6
4.12	Industrial application	II-7
4.13	Manner and order of presentation	II-7
4.14	Terminology	II-7
4.15	Computer programs	II-8
4.16	Physical values, units	II-8

PART C CONTENTS

CHAPTER I INTRODUCTION

1. General remark
2. Work of an examiner
3. Overview

CHAPTER II CONTENT OF A EUROPEAN PATENT APPLICATION (OTHER THAN CLAIMS)

1. General
2. Abstract
3. Request for grant – the title
4. Description
 - 4.1 General remarks
 - 4.2 Technical field
 - 4.3 Background art
 - 4.4 Irrelevant matter
 - 4.5 Technical problem and its solution
 - 4.6 Rule 42(1)(c) vs. Art. 52(1)
 - 4.7 Drawings
 - 4.8 Reference signs
 - 4.9 Sufficiency of disclosure
 - 4.10 Art. 83 vs. Art. 123(2)
 - 4.11 Insufficient disclosure
 - 4.12 Industrial application
 - 4.13 Manner and order of presentation
 - 4.14 Terminology
 - 4.15 Computer programs
 - 4.16 Physical values, units
 - 4.17 Proper names, trademarks and trade names
 - 4.18 Registered trademarks
 - 4.19 Reference documents
5. Drawings
 - 5.1 Form and content
 - 5.2 Printing quality
 - 5.3 Photographs
6. Inventions relating to biological material
 - 6.1 Biological material
 - 6.2 Public availability of biological material
 - 6.3 Deposit of biological material
7. Prohibited matter
 - 7.1 Categories
 - 7.2 Matter contrary to "ordre public" or morality
 - 7.3 Disparaging statements
 - 7.4 Irrelevant matter
 - 7.5 Omission of matter from publication

EPO Guidelines for Examination, April 2009

CHAPTER II – Annex UNITS RECOGNISED IN INTERNATIONAL PRACTICE AND COMPLYING WITH RULE 45(11) (see II, 4.16)

1. SI units and their decimal multiples and submultiples
 - 1.1 SI base units
 - 1.1.1 Special name and symbol of the SI unit of temperature for expressing Celsius temperature
 - 1.2 Other SI units
 - 1.2.1 Supplementary SI units
 - 1.2.2 Derived SI units
 - 1.2.3 Derived SI units having names and symbols
 - 1.3 Prefixes and their symbols used to designate certain decimal multiples and submultiples
 - 1.4 Special authorised names and symbols of decimal multiples and submultiples of SI units
2. Units which are defined on the basis of SI units but are not decimal multiples or submultiples thereof
3. Units used with the SI, and whose values in SI are obtained experimentally
4. Units and names of units permitted in specialised fields only
5. Compound units

CHAPTER III CLAIMS

1. General
2. Form and content of claims
 - 2.1 Technical features
 - 2.2 Two-part form
 - 2.3 Two-part form unsuitable
 - 2.3.1 No two-part form
 - 2.3.2 Two-part form "wherever appropriate"
 - 2.4 Formulae and tables
3. Kinds of claim
 - 3.1 Categories
 - 3.2 Number of independent claims
 - 3.3 Objection under Rule 43(2)
 - 3.4 Independent and dependent claims
 - 3.5 Arrangement of claims
 - 3.6 Subject-matter of a dependent claim
 - 3.7 Alternatives in a claim
 - 3.8 Independent claims containing a reference to another claim
4. Clarity and interpretation of claims
 - 4.1 Clarity
 - 4.2 Interpretation
 - 4.3 Inconsistencies
 - 4.4 General statements, "spirit" of invention
 - 4.5 Essential features
 - 4.6 Relative terms
 - 4.7 Terms like "about" and "approximately"
 - 4.8 Trademarks
 - 4.9 Optional features
 - 4.10 Result to be achieved
 - 4.11 Parameters
 - 4.12 Product-by-process claim
 - 4.13 "Apparatus for ...", "Method for ...", etc.
 - 4.14 Definition by reference to use or another entity
 - 4.15 The expression "in"

- 4.16 Use claims
- 4.17 References to the description or drawings
- 4.18 Method of and means for measuring parameters referred to in claims
- 4.19 Reference signs
- 4.20 Negative limitations (e.g. disclaimers)
- 4.21 "Comprising" vs. "consisting"
- 4.22 Functional definition of a pathological condition
- 5. Conciseness, number of claims
- 6. Support in description
 - 6.1 General remarks
 - 6.2 Extent of generalisation
 - 6.3 Objection of lack of support
 - 6.4 Lack of support vs. insufficient disclosure
 - 6.5 Definition in terms of function
 - 6.6 Support for dependent claims
- 7. Unity of invention
 - 7.1 General remarks
 - 7.2 Special technical features
 - 7.3 Intermediate and final products
 - 7.4 Alternatives
 - 7.4.1 Markush grouping
 - 7.5 Individual features in a claim
 - 7.6 Lack of unity "a priori" or "a posteriori"
 - 7.7 Examiner's approach
 - 7.8 Dependent claims
 - 7.9 Lack of unity during search
 - 7.10 Lack of unity during substantive examination
 - 7.10.1 Amended claims
 - 7.11 Euro-PCT applications
 - 7.11.1 International applications without supplementary search
 - 7.11.2 International applications with supplementary search
 - 7.11.3 International preliminary examination report (IPER)
 - 7.11.4 Restricted IPER
- 8. Different texts of the patent application in respect of different Contracting States (see also D-VII, 4)
 - 8.1 Different text in respect of the state of the art according to Art. 54(3)
 - 8.2 Different text where a partial transfer of right has taken place pursuant to Art. 61
 - 8.3 Different text where a reservation has been entered in accordance with Art. 167(2)(a) EPC 1973
 - 8.4 Different text where national rights of earlier date exist
 - 8.5 Calculation of claims fees

CHAPTER IV PATENTABILITY

- 1. General
 - 1.1 Basic requirements
 - 1.2 Further requirements
 - 1.3 Technical progress, advantageous effects
- 2. Inventions
 - 2.1 Exclusions
 - 2.1.1 Discoveries
 - 2.1.2 Scientific theories
 - 2.1.3 Mathematical methods
 - 2.1.4 Aesthetic creations
 - 2.2 Examination practice
 - 2.3 List of exclusions
 - 2.3.1 Discoveries
 - 2.3.2 Scientific theories
 - 2.3.3 Mathematical methods
 - 2.3.4 Aesthetic creations
 - 2.3.5 Schemes, rules and methods for performing mental acts, playing games or doing business
 - 2.3.6 Programs for computers
 - 2.3.7 Presentations of Information
- 3. Biotechnological Inventions
 - 3.1 General remarks and definitions
 - 3.2 Patentable biotechnological inventions
- 4. Exceptions to patentability
 - 4.1 Matter contrary to "ordre public" or morality
 - 4.2 Prohibited matter
 - 4.3 Offensive and non-offensive use
 - 4.4 Economic effects
 - 4.5 Biotechnological inventions
 - 4.6 Plant and animal varieties, processes for the production of plants or animals
 - 4.6.1 Plant varieties
 - 4.6.2 Processes for the production of plants or animals
 - 4.7 Microbiological processes
 - 4.7.1 General remarks
 - 4.7.2 Repeatability of results of microbiological processes
 - 4.8 Surgery, therapy and diagnostic methods
 - 4.8.1 Limitations of exception under Art. 53(c)
- 5. Industrial application
 - 5.1 General remarks
 - 5.2 Method of testing
 - 5.3 Industrial application vs. exclusion under Art. 52(2)
 - 5.4 Sequences and partial sequences of genes
- 6. State of the art
 - 6.1 General remarks and definition
 - 6.2 Enabling disclosures
 - 6.3 Date of filing or priority date as effective date
 - 6.4 Documents in a non-official language
- 7. Conflict with other European applications
 - 7.1 State of the art pursuant to Art. 54(3)
 - 7.1.1 Requirements
 - 7.2 Euro-PCT applications
 - 7.3 Commonly designated States
 - 7.4 Double patenting
- 8. Conflict with national rights of earlier date
- 9. Novelty
 - 9.1 State of the art pursuant to Art. 54(2)
 - 9.2 Implicit features or well-known equivalents
 - 9.3 Relevant date of a prior document
 - 9.4 Enabling disclosure of a prior document
 - 9.5 Generic disclosure and specific examples
 - 9.6 Implicit disclosure and parameters
 - 9.7 Examination of novelty
 - 9.8 Selection inventions
- 10. Non-prejudicial disclosures
 - 10.1 General
 - 10.2 Time limit
 - 10.3 Evident abuse
 - 10.4 International exhibition
- 11. Inventive step
 - 11.1 General
 - 11.2 State of the art; date of filing
 - 11.3 Person skilled in the art
 - 11.4 Obviousness
 - 11.5 Combination vs. juxtaposition or aggregation

- 11.6 Origin of an invention
- 11.7 Problem-and-solution approach
 - 11.7.1 Determination of the closest prior art
 - 11.7.2 Formulation of the objective technical problem
 - 11.7.3 Could-would approach
- 11.8 Combining prior-art documents
- 11.9 Indicators
 - 11.9.1 Predictable disadvantage; non-functional modification; arbitrary choice
 - 11.9.2 "Ex post facto" analysis; surprising technical advantage
 - 11.9.3 Unexpected technical effect; bonus effect
 - 11.9.4 Long-felt need; commercial success
- 11.10 Arguments and evidence submitted by the applicant
- 11.11 Selection inventions
- 11.12 Dependent claims; claims in different categories
- 11.13 Examples

CHAPTER IV – Annex EXAMPLES RELATING TO THE REQUIREMENT OF INVENTIVE STEP – INDICATORS (see IV, 11.13)

1. Application of known measures?
 - 1.1 Inventions involving the application of known measures in an obvious way and in respect of which an inventive step is therefore to be ruled out:
 - 1.2 Inventions involving the application of known measures in a non-obvious way and in respect of which an inventive step is therefore to be recognised:
2. Obvious combination of features?
 - 2.1 Obvious and consequently non-inventive combination of features:
 - 2.2 Not obvious and consequently inventive combination of features:
3. Obvious selection?
 - 3.1 Obvious and consequently non-inventive selection among a number of known possibilities:
 - 3.2 Not obvious and consequently inventive selection among a number of known possibilities:
4. Overcoming a technical prejudice?

CHAPTER V PRIORITY

"EPO Guidelines for Examination, April 2009, Part C, Chapters I-IV" is included on PDF as a general reference. **Reading this material is strongly recommended for this course.**

Note: Some of the slides of this course (those in English with a number at the beginning of the paragraph) are taken from an older version of the EPO Guidelines. Their numbering may vary in respect to the current version, but their contents virtually not.



MINISTERIO
DE INDUSTRIA, TURISMO
Y COMERCIO



Oficina Española
de Patentes y Marcas

¡Un hito en la historia de la OEPM!

Versión 0 (183 pp. Lunes de Patentes 2.10.2006)

Versión 1 (175 pp., finales de octubre 2006) Archivo PDF de 500 Kb,
descargable de: www.oepm.es / invenciones / patente nacional / todo lo que
necesitas saber... / el proceso de tramitación paso a paso

DIRECTRICES DE EXAMEN DE SOLICITUDES DE PATENTE

Módulo ampliado de Redacción

La práctica de la redacción de memorias y reivindicaciones

Fechas

Barcelona: 9-12 de marzo

Madrid: 23-26 de noviembre

Profesor

Pascual Segura

Licenciado en química por la Universidad de Valencia y doctor por la Universidad de Barcelona. Agente de la propiedad industrial de la UB y director de su Centro de Patentes. Member of the first Academic Advisory Board of the European Patent Academy, EPO. President de la secció tècnica "Patents" del Col.legi Oficial de Químics de Catalunya.

Contenido

- **Generalidades.** Obtener la mejor protección posible como objetivo. Aspectos previos a decidir. Alcance de la protección, derechos conferidos y actos prohibidos. Intentar que la posible infracción sea directa y literal (no indirecta o por equivalencia). Elementos estructurales, funcionales, intencionales y paramétricos. *Comprising vs. consisting of*. Procurar incluir reivindicaciones (reivs.) de entidad (= producto), además de reivs. de actividad (= procedimiento o método). Control de costes asociados al número de págs. y al número de reivs.
- **Metodología general para redactar reivindicaciones.** Cubrir todos los posibles actos infractores. No reivindicar lo que tenemos, sino lo que el estado de la técnica no tiene. Reivindicar la invención, no el producto. Reivindicar la invención *on the shelf* y a un nivel adecuado. Identificar el elemento nuevo. Seleccionar la categoría de la reiv. Escoger su "nombre o sujeto". Chequear su validez (¿es nueva? ¿tenemos algún argumento para justificar su actividad inventiva?)

A quién va dirigido

A quien tenga conocimientos sobre patentes o que haya asistido al módulo de Fundamentos. Está especialmente dirigido a técnicos que quieran realizar o controlar la redacción de solicitudes de patentes preparadas para OEPM, PCT, EPO y USPTO. Se necesitan conocimientos de inglés

Contenido (cont.)

¿es un mero desiderátum?) Chequear su infracción (¿tiene algún elemento o palabra demasiado limitante? ¿protege lo que se fabrica o vende? ¿es autosuficiente?).

- **Metodología para redactar reivindicaciones dependientes.** Jerarquizar la importancia comercial de los elementos. Partir de una reiv. para el mejor prototipo disponible, y progresivamente eliminar-generalizar-combinar sus elementos. Diseñar estructuras de dependencias apropiadas (pirámide, cadena, cadenas-en-pirámide, selección de ramas por separado, selección de ramas simultáneamente, etc.). Dependencia múltiple para crear posiciones de retroceso.
- **Tipos especiales de reivindicaciones.** Reivs. de medio-más-función. Reivs. en-dos-partes (*Jepson*), con *characterized in that*. Casos en los que resultan apropiadas y casos en los que no. Uso obsoleto de "caracterizado por" en reivs. que realmente no son en-dos-partes, o en reivs. dependientes. Reivs. con grupos de Markush. Reivs. de productos definidos por parámetros. Reivs. *product-by-process*. Reivs. con "para" (*purpose-limited product claims*). La 1ª y 2ª indicación terapéutica como excepciones. Reivs. de *method of treatment* en US. Reivs. de uso. Reivs. de procedimiento de obtención. Reivs. de procedimiento de simple mezcla. Anticipación accidental y *disclaimers*.
- **La claridad** como principal habilidad del redactor. La aproximación *KISS (Keep It Short and Simple)*. Ser claro, sin resultar farragoso ni prolijo. A un mismo elemento designarlo siempre con un único nombre (o acrónimo) y con un único número (si procede). Trucos. **La unidad de invención** y su trascendencia económica. Directrices consensuadas PCT-EPO-USPTO. Prever las modificaciones posteriores durante el examen, para que no impliquen **adición de materia nueva**.
- **Cuestiones formales sobre presentación de solicitudes.** Partes de una solicitud de patente. Normas generales para presentar la solicitud. Elaboración de un archivo-plantilla para controlar márgenes, paginación, espaciado, numeración de líneas, tipo de letra, etc. Subtítulos y notas precautorias en el archivo-plantilla. Confeción de dibujos, gráficas y fotos. Biosecuencias y el programa *Patent-In*.



La práctica de la redacción de memorias y reivindicaciones

Contenido (cont.)

- **Cuestiones prácticas sobre redacción de memorias.** Qué no puede -o no debe- incluirse en la memoria. Mantener flexible la definición de la invención. Redactar en inglés sencillo, con la terminología y simbología habituales. "Inventarse" nueva terminología si conviene. Evitar los "falsos amigos" del inglés. Usar títulos que no sean "demasiado" descriptivos. El campo de la técnica. La parte del estado de la técnica (*background art*) como educación de los potenciales lectores y preparación de argumentos de actividad inventiva, señalando limitaciones, inconvenientes o prejuicios que supera la invención. Aprovechar la bibliografía de los inventores y/o realizar nuevas búsquedas. Cómo citar documentos. Incorporar el texto de las reivs. a la explicación (*summary*) de la invención, "contando la historia" para que la pueda entender un directivo y un juez. Procurar suficiencia de descripción y soporte para todas las reivs. Mencionar ventajas reales, sin hacer afirmaciones despreciativas. Rangos (*ranges*) y fórmulas generales. *Fallback positions* según se desee permitir o impedir futuras invenciones de selección. Ejemplos y realizaciones detalladas: su distribución y su reproducibilidad. El requisito US de *best mode*. Esquema típico en electromecánica: estructura, funcionamiento, fabricación, ventajas y variantes. El resumen (*abstract*). Trucos para ahorrar espacio.
- **Cuestiones prácticas sobre inventores.** La identificación correcta de los inventores y su importancia. Inventoría vs. propiedad. Errores típicos de los inventores. Tipos de inventores. Entrevistas con el inventor de contacto: delimitar los límites de no-funcionamiento; buscar elementos equivalentes.
- **Ejemplos y ejercicios prácticos** de química, farmacia, biotecnología, electromecánica e informática, distribuidos a lo largo de toda la exposición.

El inventor es el protagonista principal de la invención. El técnico redactor de patentes es fundamental para protegerla. Y la colaboración del abogado especializado lo es para transferir o hacer valer sus derechos.

Títulos oficiales

ES: agente de la propiedad industrial

EP: European patent attorney

US: patent agent & patent attorney

GB: patent agent

DE: Patentanwalt



Managing Intellectual Property surveys (Spain)

2007

2008

2009

2010

PATENT PROSECUTION	
Tier 1	ZBM Patents
Tier 2	ABG Patentes Elzaburu Herrero y Asociados
Tier 3	Currell Suñol Durán-Corretjer J Isern Patentes y Marcas Sugranes Oficina Tecnico Juridica Ungria Patentes y Marcas, SA
Tier 4	Bird & Bird Carlos Polo y Asociados Clarke Modet & Co Garrigues Jacobacci & Partners Oficina Ponti

PATENT PROSECUTION	
Tier 1	ABG Patents Elzaburu Herrero y Asociados ZBM Patents
Tier 2	Curell Suñol Durán-Corretjer J Isern Patentes y Marcas Sugranes Oficina Tecnico J
Tier 3	Bird & Bird Carlos Polo y Asociados Clarke Modet & Co Garrigues Jacobacci & Partners Oficina Ponti Pons Roland & Douglas Ungria Patentes y Marcas,

PATENT PROSECUTION	
Tier 1	Elzaburu Herrero y Asociados ZBM Patents
Tier 2	ABG Patentes Curell Suñol Durán-Corretjer Oficina Ponti Pons Sugranes Oficina Tecnico J
Tier 3	Carlos Polo y Asociados Clarke Modet & Co Jacobacci & Partners Ungria Patentes y Marcas
Tier 4	Garrigues J Isern Patentes y Marcas Roland & Douglas

PATENT PROSECUTION	
TIER 1	ABG Patentes Elzaburu Herrero y Asociados ZBM Patentes
TIER 2	Clarke Modet & Co Curell Suñol Pons Sugranes Oficina Técnico
TIER 3	Durán-Corretjer Garrigues Jacobacci & Partners Oficina Ponti Ungria Patentes y Marcas
TIER 4	Carlos Polo y Asociados J Isern Patentes y Marcas

Objetivo del curso

El curso tiene por objetivo formar candidatos españoles que quieran mejorar su práctica profesional y presentarse al *European Qualifying Examination (EQE)* para convertirse en Agentes de Patentes Europeas, esencialmente a través de casos prácticos y con la orientación del Convenio de la Patente Europea. Para información sobre el EQE, ver www.epo.org. Este Primer Año del curso está programado para que los candidatos puedan presentarse a la Prueba A (redacción) y a la Prueba B (modificaciones) del examen en 2011, contando con la asistencia de los tutores a lo largo de toda la preparación. Entre marzo de 2011 y enero de 2012 se ofrecerá un Segundo Año preparatorio para presentarse en 2012 a la Prueba C (oposición) y a la D (jurídica).

Curso organizado por



Centre de Patents
de la Universitat de Barcelona



Curso práctico para preparar el *European Qualifying Examination (EQE)*

V Edición, Primer Año
Prueba A (redacción) y
Prueba B (modificaciones)

Madrid y Barcelona, marzo 2010 - enero 2011

★ = del sector
química-farma-
biotec

LOS 50 MAYORES SOLICITANTES DE PATENTES EUROPEAS PRESENTADAS EN ESPAÑA, 2008

Solicitantes		
	Sistemas Tec. De Encofrados, Sa	Teilo Alabarte, S.L.
	Trenzametal, S.L.	Arturo Jiménez Bayardo
Labo.Dr. Esteve, S.A. ★	Alcatel España, S.A.	Bankinter, S.A.
Vodafone España, Sa	Dow Golobal Techonologies Inc.	Caspro, S.A.
Seat, S.A.	Eli Lilly and Company ★	Celaya, Emparanza y Galdós
Laboratorios Almirall, S.★	Fagor	Cellerix, S.A. ★
Jane, S.A.	Grupo Antolín Ingeniería, S.A.	Cerámica Acustica, S.L.
Pharma Mar, S.A. ★	Orona S,Coop.	Climastar Global Company S.A.
Airbus España, SI	Accenture Global Services	Construcciones ; Técnicas de Rai
Dalphi Metal España, S.A.	Bsh Electr. España S.A.	Electrodomésticos Taurus, S.L.
Grifols, S.A. ★	Chemo Ibérica, S.A. ★	Facet Iberica, S.A
Pangaea Biotech ★	Fundación Robotiker	Font I Mas, Juan Carlos
Thyssenkrupp Elevador Lti	Gh Electrotermia, Sa	Fresmak, S.A.
Giro Gh, S.A.	Lacer, S.A. ★	Gmv Aerospace and Defence S.A
Glaxo Group Limited ★	Metalast, S.A.U.	Grupo Sagola S. de Promicion de
Palau Pharma, S.A. ★	Ojmar, S.A.	Inke, S.A. ★
	Pedro Zabilde	Insca Internacional S.L.
	Promociones Brial S.L.	
	Ribawood, S.A.	

Jornadas organizadas por



Jornadas de estudio y actualización en materia de patentes

"Los Lunes de Patentes"

Foro de aprendizaje y discusión

Las Jornadas de estudio y actualización en materia de patentes ("Los Lunes de Patentes") son un foro de aprendizaje y discusión, gratuito, profesional y abierto a todas las opiniones. Desde comienzos de 2001, cuatro o cinco lunes al año se reúnen personas interesadas en formarse sobre patentes (incluyendo modelos de utilidad y diseños industriales) desde un punto de vista profesional, independientemente de su especialidad y del lugar trabajo.

Funcionamiento

Para funcionar de la manera más sencilla posible, no hay ningún coste de inscripción ni de documentación y no es necesario comunicar la intención de asistir. El local lo proporciona la OEPM o el Centro de Patentes de la UB.

Y la documentación, que suele ser voluminosa, se distribuye por correo electrónico y colgándola en la página web www.pcb.ub.es/centredepatents

Recientes cambios en el Reglamento del Convenio sobre concesión de Patentes Europeas: ¡A correr!

Anna Barlocchi

Qualified European Patent Attorney y socia fundadora de ZBM Patents; coordinadora del "Curso práctico para preparar el *European Qualifying Examination*" de la OEPM y el Centre de Patents de la UB

y Mathieu de Rooij

Qualified European Patent Attorney de ZBM Patents; antiguo examinador de la EPO

Conflictos entre innovadores y genéricos sobre la aplicación de la normativa relativa a patentes farmacéuticas en España: Crónica de una 'guerra' con varios frentes, narrada por un observador independiente

Pascual Segura

Agente de la propiedad industrial de la UB y director de su Centro de Patentes

**EN ESTA SECCIÓN LOS QUÍMICOS SIEMPRE
ENCONTRARÁN ORIENTACIÓN PROFESIONAL EN EL
[APASIONANTE] MUNDO DE LAS PATENTES**



*Presentació
Escola de Graduats
Borsa de treball*



S

Seccions tècniques

S.T. Patents